Benign Hematological Disorders

328

3. ยาสเตียี รอยด์ช์ นิดิ อนาบอลิกิ (ananbolic จากให้ย้ าต่อ่ เนื่่�องแล้้วอย่่างน้อ้ ย 6 เดืือน หากผู้้�ป่ว่ ยไม่ด่ ีี
steroid) ขึ้น� แม้ว้ ่่าจะให้ย้ าต่อ่ เนื่่อ� งเกินิ 6 เดืือน ถืือว่่าไม่ต่ อบสนอง
ต่อ่ การรัักษา หากผู้้�ป่ว่ ยตอบสนองต่อ่ การรัักษา ควรให้ย้ า
เป็็นยาที่�่นำมาใช้้รัักษาโรคไขกระดููกฝ่่อเป็็น ต่อ่ เนื่่อ� งรวมอย่า่ งน้อ้ ย 12 เดืือนแล้ว้ ลดยาลงช้า้ ๆ จนหยุดุ
ชนิิดแรก ๆ ก่่อนหน้้านี้้�มีีการใช้้อย่่างแพร่่หลายทั้้�ง ยาใน 18 เดืือน22
Methandrosterone, Oxymetholone, Nandrolone, ระหว่่างที่่�ให้้ยา หากพบว่่าค่่าตัับผิิดปกติิ ควร
Danazol เป็็นต้้น แต่่เนื่่�องด้้วยผลการตอบสนองไม่่ได้้ พิิจารณาหยุุดยาชั่่�วคราว จนกว่่าผลการตรวจจะกลัับ
ผลที่�่ดีีเทีียบเท่่ากัับการปลููกถ่่ายไขกระดููก หรืือการใช้้ เป็น็ ปกติิ
ยากดภููมิิ และอาจเกิิดผลข้้างเคีียงมาก จึึงแนะนำให้ใ้ ช้ใ้ น ปฏิกิ ิิริยิ าอัันไม่่พึงึ ประสงค์1์ 4
severe aplastic anemia เป็็นลำดัับที่่ส� อง (2nd line
treatment) หรืือแนะนำให้้ใช้ใ้ น non-severe aplastic ผลข้้างเคีียงที่่�พบบ่่อย ทำให้้มีีลัักษณะเพศชาย
anemia เป็น็ ลำดัับแรก หรืือในกรณีีที่ไ�่ ม่ต่ อบสนองต่อ่ การ มากขึ้น� (Androgenic effect) เช่น่ เสีียงห้้าว ผิวิ หยาบ
รัักษาตามมาตรฐานใดๆ หรืือเป็็นโรคไขกระดููกฝ่่อแต่่ เป็น็ สิวิ มีีหนวด มีีขนตามร่า่ งกายและใบหน้า้ มากขึ้น� หาก
กำเนิิดบางชนิิด ก็็สามารถพิิจารณาการใช้้ยาสเตีียรอยด์์ เป็็นเพศชายอาจพบว่่ามีีอวััยวะเพศตื่่�นตััวบ่่อยมากขึ้ �น
ชนิิดอนาบอลิิกได้้ ซึ่�งยาที่�่มีีผลการตอบสนองที่�่ดีี และใช้้ หรืือภาวะเตานมโต (gynecomastia) และเพศหญิิงอาจ
อย่่างแพร่่หลายในปััจจุุบััน คืือ Oxymetholone และ พบว่า่ ประจำเดืือนมาไม่่ปกติิได้้ ดัังนั้้�นก่อ่ นการให้ย้ าชนิิด
Danazol10,14,15 นี้้� ควรอธิิบายให้้ผู้้�ป่่วยทราบถึึงผลข้้างเคีียงของยา
กลไกการออกฤทธิ์�์10,14,15 นอกจากนี้้� อาจเกิดิ ลิ่่ม� เลืือดในกระแสเลืือดได้้ (thrombo-
embolism)
- กระตุ้�นการสร้้าง erythropoietin ในผู้้�ป่่วยเด็็กที่่� epiphysis ยัังไม่่ปิิด ซึ่ง� มัักมีีอายุุ
- เพิ่่�มความไวของ erythroid target organ น้้อยกว่่า 15 ปีี การได้้รัับยานี้้�อาจทำให้เ้ กิดิ premature
และ bone marrow activity จากการกระตุ้�นของ eryth- epiphyseal closure ได้้ ที่ผ�่ ่่านมามีีการให้ย้ า prednis-
ropoietin olone ขนาดต่่ำร่ว่ มด้ว้ ยเพื่่อ� ป้้องกัันภาวะนี้้� แต่่ไม่ม่ ีีหลััก
- กระตุ้�นการเจริิญเติิบโตของ hematopoiet- ฐานที่่�น่า่ เชื่อ� ถืือมากพอในการลดผลข้า้ งเคีียงนี้้�
ic stem cell รวมทั้้�ง erythroid และ granulocyte แม้้ว่่าการรัักษาโรคไขกระดููกฝ่่อ จะมีีการรัักษา
colony เพื่่อ� มุ่�งเน้น้ ให้ห้ ายขาดที่ม่� ีีแนวทางชััดเจน ไม่ว่ ่า่ จะเป็น็ การ
- เพิ่่ม� iron incorporation เข้า้ สู่�เซลล์เ์ ม็ด็ เลืือด ปลููกถ่่ายไขกระดููก การให้้ยากดภููมิิ และการให้้ยาอื่�น ๆ
แดง แต่่อย่่างไรก็็ตาม การรัักษาแบบประคัับประคอง ซึ่�ง
การให้ย้ า ประกอบด้้วย การให้ผ้ ลิติ ภััณฑ์จ์ ากเลืือดที่เ�่ หมาะสม การ
ป้้องกัันและรัักษาโรคติิดเชื้้�อ โดยการให้้ยาปฏิิชีีวนะ ยา
ขนาดยาที่่�ใช้้ได้้แก่่ oxymetholone ขนาด 2-5 ต้้านเชื้้�อราหรืือยาต้้านไวรััส และการให้้คำแนะนำในการ
มก./กก./วััน หรืือ danazol 200-800 มก./วััน การให้้ยา ปฏิบิ ััติิตััวของผู้้�ป่่วย และผู้้�ดูแู ล เป็็นสิ่ง� ที่�่สำคััญที่�่จะทำให้้
สามารถให้้วัันละครั้�ง ก่่อนหรืือหลัังอาหารก็็ได้้ ก่่อนการ มีีอััตราการรอดชีีวิติ สูงู และผู้้�ป่่วยมีีคุณุ ภาพชีีวิติ ที่�่ดีี
ให้้ยา ควรมีีการตรวจค่่าตัับเป็็นพื้�้นฐาน และตรวจเป็็น
ประจำทุกุ 2-3 เดืือน เนื่่อ� งจากยาสามารถทำให้ก้ ารทำงาน
ของตัับผิิดปกติิได้้ และมีีการประเมิินผลการรัักษา หลััง

329

Reference 10. Jaime-Pérez JC, Colunga-Pedraza PR,
Gómez-Ramírez CD, et al. Danazol as first-line
1. Montane E, Ibanez L, Vidal X, Ballarin therapy for aplastic anemia. Ann Hematol
E, Puig R, Garcia N, et al. Epidemiology of aplastic 2011;90:523-7.
anemia: a prospective multicenter study. Haema- 11. Olnes MJ, Scheinberg P, Calvo KR, et
tologica. 2008;93:518-23. al. Eltrombopag and improved hematopoiesis in
2. Issaragrisil S, Kaufman D, Anderson T, refractory aplastic anemia. N Engl J Med
et al. The epidemiology of aplastic anemia in 2012;367:11-9.
Thailand. The Aplastic Anemia Study Group. Blood 12. Lee JW, Lee SE, Jung CW, et al. Romi-
2006;107:1299-370. plostim in patients with refractory aplastic anae-
3. Young NS, Calado RT, Scheinberg P. mia previously treated with immunosuppressive
Current concepts in the pathophysiology and therapy: a dose-finding and long-term treatment
treatment of aplastic anemia. Blood 2006;108:2509- phase 2 trial. Lancet Haematol 2019;6:e562-e572
19. 13. Narita A, Zhu X, Muramatsu H, et al.
4. Young NS, Bacigalupo A, Marsh J. Aplas- Prospective randomized trial comparing two
tic anemia: Pathophysiology and treatment Biol doses of rabbit anti-thymocyte globulin in pa-
Blood Bone Marrow Transplant. 2010; 16:S119-25. tients with severe aplastic anaemia. Br J Haema-
5. Bacigalupo A, Passweg J. Diagnosis and tol 2019;187:227-37.
treatment of acquired aplastic anemia. Hematol 14. Shahami S, Braga-Barsaria M, Maggio
Oncol Clin N Am 2009; 23:159-70. M, et al. Androgen and erythropoiesis: past and
6. Marsh JCW, Ball S, Cavenagh J, et al. present. J Endocrinol Invest 2009;32: 740-6.
Guideline for the diagnosis and management of 15. Chuhjo T, Yamazaki H, Omine M,
aplastic anemia. Br J Haematol 2009;147:43-70 Nakao S. Danazol therapy for aplastic anemia
7. Bacigalupo A. How I treat acquired refractory to immunosuppressive therapy. Am J
aplastic anemia. Blood 2017;129:1428-36. Hematol 2008;83:387-9.
8. Gurion R, Gafter-Gvili A, Paul M, Vidal 16. Qian H, Buza-Vidas N, Hyland CD,
L, et al. Hematopoietic growth factors in aplastic Jensen CT, Antonchuk J, Månsson R, et al. Critical
anemia patients treated with immunosuppressive role of thrombopoietin in maintaining adult qui-
therapy-systematic review and metaanalysis. escent hematopoietic stem cells. Cell Stem Cell.
Haematologica. 2009;94:712-9. 2007;1:671-84.
9. Scheinberg P, Nunez O, Weinstein B,
et al. Horse versus rabbit antithymocyte globulin
in acquired aplastic anemia. N Engl J Med.
2011;365:430-8.

330

17. Imbach P, Crowther M. Thrombopoi-
etin-Receptor Agonists for Primary Immune
Thrombocytopenia. N Engl J Med 2011;365:734-41
18. Desmond R, Townsley DM, Dumitriu
B, Olnes MJ, Scheinberg P, Bevans M, et al. El-
trombopag restores trilineage hematopoiesis in
refractory severe aplastic anemia that can be
sustained on discontinuation of drug. Blood.
2014;123:1818-25.
19. Townsley DM, Scheinberg P, Winkler
T, Desmond R, Dumitriu B, Rios O, et al. Eltrom-
bopag Added to Standard Immunosuppression
for Aplastic Anemia. N Engl J Med. 2017;376:1540-
50.
20. Teramura M, Kobayashi S, Iwabe K,
Yoshinaga K, Mizoguchi H. Mechanism of action
of antithymocyte globulin in the treatment of
aplastic anaemia: in vitro evidence for the pres-
ence of immunosuppressive mechanism Br J
Haematol. 1997;96(1):80-4.
21. Mohty M, Mechanisms of action of
antithymocyte globulin: T-cell depletion and
beyond. Leukemia. 2007;21(7):1387-94.
22. สมาคมโลหิิตวิิทยาแห่่งประเทศไทย,
แนวทางการรัักษาโรคไขกระดููกฝ่่อ (Guideline for
diagnosis and management of aplastic anemia).
พ.ศ. 2563.

 

Index

Symbol Actin polymerization 157
Actin-binding protein 123
α-globin 2, 24 Activated factor VIII 36
α-globin chain imbalance 27 Activated partial thromboplastin time
α-globin gene cluster 23
α-spectrin 122 38, 107, 115, 215, 218
α-thalassemia 1, 24, 30 Activated protein C 45
α-thalassemia 1 trait 24, 25 Activated prothrombin complex concentrate 44
α-thalassemia 2 trait 24, 25 Activation peptide 36
α-thalassemia trait 287 Activin 193
β-globin 2, 24 Acute myeloid leukemia 141
β-globin chain imbalance 5, 16 Acute GvHD 260
β-globin gene cluster 1 Acute hemolytic transfusion reaction 235
β-spectrin 122 Acute kidney injury 241
β-thalassemia 1, 2, 149 Acute leukemia 60
β-thalassemia trait 287, 313 Acute lymphoblastic leukemia 141
β-thalassemia/Hb E 1, 7, 8 Acute myeloid leukemia 136, 137, 139
Acute pulmonary reaction 243
A Acute tubular necrosis 241
Adenomyosis 196
Abnormal splicing 7 Adenovirus 151, 265, 266
Abnormalities of alpha-granule 94 Adhesion 91
ABO grouping 235 Adhesive defect 93
ABO incompatible red blood cell 241 Adipocyte 136
Absolute lymphocyte count 147 ADP receptor defect 94
Absolute neutrophil count 140, 155 Adrenal insufficiency 253
Absorbable gelatin foam 187 AE Bartûs disease 28
Acanthocyte 130, 131 Afibrinogenemia 109
Acceptance 270 Agammaglobulinemia 146, 148, 152, 154
Achondroplasia 282 Agenda 275
Acquired aplastic anemia 135, 257 Agranulocytosis 14
Acquired mutation 280 Airflow 179
Acquired prothrombin complex deficiency 113, 299 Albutrenonacog alfa 42
Acquired prothrombotic risk factors 212 Alkaline phsphatase 252
Acrohydria 173 Alkalinized diuresis 131
Actin 91 Allele-specific amplification 283, 286

332 Index

Allogeneic hematopoietic stem cell transplantation 258 Anterior epistaxis 180, 184
Alloimmune 242 Anterior fossa 85
Alloimmunization 99 Anterior nasal packing 187
Alpha fetoprotein 79 Anterior pituitary gland 191
Alpha-granule 91, 94 Anti beta2-glycoprotein I 212
Alternative donor 137, 138, 259 Anti-D immunoglobulin 64
Alternative pathway 149, 161 Anti-double-stranded DNA 310, 311
Amblyopia 80 Anti-factor Xa 218
American Association of Blood Bank 236 Anti-smith 310
American Society of Hematology 61 Antibiotic prophylaxis 151, 154, 157, 160
Amikacin 300 Antibody 57, 235, 241, 242, 243
Amino acid 36 Antibody screening 237
Amniocentesis 31, 50 Anticardiolipin antibody 212
Amplification phase 106, 107 Anticoagulant pathway 45
Amplification refractory mutation system 286, 288 Anticoagulation protein 216
Anaerobic glycolysis pathway 127 Antifibrinolytic agent 99, 111, 204
Anamnestic response antibody 242 Antigen 59, 241, 243
Anaphylactic reaction 37, 153 Antihistamine 245
Anaphylaxis 63 Antinuclear antibody 61, 310, 311
Androgen 137, 140 Antioxidant pathway 127
Androgen-dependent gene expression 37 Antiphospholipid antibody 38, 61, 212, 309, 310
Anemia 306, 308 Antiphospholipid syndrome 57, 227
Anemia of chronic disease 168, 170 Antithrombin 45, 211, 214, 215
Anemia of inflammation 168 Antithrombin concentrate 215
Anger 270 Antithrombotic agents 216, 217
Angiocentric vascular sarcoma 85 Antithymocyte globulin 261, 263
Angioedema 161 Aortic coarctation 77
Angiofibroma 73, 85 APC-specific serpin 45
Angiogram 232 APGAR score 297, 302, 305, 315
Angiography 85 Apheresis 236
Angiosarcoma 73, 79, 81, 85 Aplastic anemia 60
Anisocytosis 168 Apoptosis 58, 138
Ankyrin 121, 124 Arachidonic acid 98
Annualized bleeding rate 45 Aromatization 192
Anorexia 168 Arrhythmia 227
Anovulation 197 Arterial anomalies 77
Anovulatory bleeding 205, 309 Arterial dissection 227, 229
Anovulatory DUB 196, 205 Arterial embolization 187

Index 333

Arterial stroke 216, 226 B
Arterial thromboembolism 215 B cell 145
Arteriovenous malformation 78 B domain 36
Arthritis 159 Band 3 119, 121, 124, 306, 307
Ascorbic acid 165 Band 3 macrocomplex 120
Aseptic meningitis 63 Bargaining 270
Aspergillus fumigatus 156 Basket cell 127
Aspergillus species 260 Basolateral membrane 166
Aspirin 183, 189, 230, 232, 245 Beckwith-Wiedemann syndrome 78
Asymmetrical SGA 297 Bedside filtration 11
Asymptomatic 28, 119 Benign 75
Ataxia 139 Bernard-Soulier syndrome 60, 93, 184
Ataxia telangiectasia 146 Beta-thromboglobulin 91, 94
Atherosclerosis 225 Beta2-glycoprotein 309
Atransferrinemia 167 Bethesda unit 43
Atrophic glossitis 168 Bilateral radial aplasia 97, 140
Autoantibody 58, 63, 173 Bile pigment 6
Autoimmune 161, 242 Bispecific antibody 46
Autoimmune cytopenia 152, 161 Bisphosphonates 253
Autoimmune disease 135, 145, 173 Bleeding disorder 287
Autoimmune hemolytic anemia 61, 152, 310, 311 Bleeding time 93, 94, 95
Autoimmune lymphoproliferative syndrome 61, 146, 161 Blood group 305
Autoinflammatory 146, 162 Blood transfusion 124, 289
Autologous hematopoietic stem cell transplantation 258 Blood warmer 237
Automated DNA sequencing 286 Body disproportion 250
Autonomy 270 Bone age 250, 254
Autosomal dominant 77, 94, 95, 121, 122, Bone deformity 5, 252
Bone disease 5
126, 137, 139, 140, 303 Bone marrow 135, 259
Autosomal dominant hyper-IgE syndrome 160 Bone marrow harvest 259
Autosomal recessive 18, 23, 93, 94, 95, 97, 105, Bone marrow cavity 252
Bone marrow collection 258
106, 108, 110, 113, 136, 137, 138, 139, 140, Bone marrow expansion 5
151, 152, 156, 279 Bone resorption 252
Azathioprine 172 Braddock Carey microdeletion syndrome 317
Azithromycin 154 Bradykinin 161
Britsh Committee for Standards in Hematology 101
Bronchiectasis 152, 154
Burkholderia spp. 156
Bypassing agent 44, 45, 48

334 Index

C Chlorpheniramine 11, 12, 243, 245
C1q deficiency 161 Cholecystectomy 126
C3 deficiency 161 Chorionic villus sampling 31, 50
Cafe-au-lait spot 136 Chromosome 22q11.2 deletion 159
Calcium 107, 252, 253, 254 Chromosome instability disorder 139
Campylobacter jejuni 152 Chromosome microarray 317
Candida 151 Chronic anovulation 197
Candida albicans 156 Chronic enteroviral meningoencephalitis 152
Candida species 260 Chronic granulomatous disease 113, 146, 149, 156,
Capillary electrophoresis 10, 312
Capillary hemangioma 83 300, 301
Carbon 192 Chronic GvHD 260
Carbot ring 175 Chronic hemolytic anemia 6
Carboxyglutamic acid domain 110 Chronic ITP 58, 59, 93
Cardiac anomalies 77 Chronic synovitis 47
Cardiac catheterization 212 Circumcision 37
Cardiopulmonary bypass 239 Citrate 165
Cardiogenic emboli 227 Classical pathway 149
Carrier testing 279, 294 Clopidogrel 94, 232
Cartilage 47 Clot retraction 98
Catalytic domain 36, 110 Clumped pigmentation 161
Cataract 95 Coagulation cascade 105
Catheter-related VTE/ATE 215 Coagulation factor 216, 299
Cavernous hemangioma 73, 77 Coagulation pathway 45
CD marker 148, 151 Coagulogram 84, 198, 216, 298, 299, 302,
CD40 ligand deficiency 153
Celiac disease 170 303, 308, 316
Central venous catheter 211 Coagulopathy 196
Cephalohematoma 110 Cobalamin 171, 173
Cerebral sinovenous thrombosis 226 Cocaine 227
Cerebellar hypoplasia 139 Cognitive behavioral therapy 276
Cerebrovascular disease 225 Cohn fractionation process 41
Ceroid 95 Cold intolerance 168
Chediak-Higashi syndrome 95, 146, 160 Collagen 38, 93, 98, 105
Chemical cauterization 186 Collagen receptor defect 93
Chest x-ray 148 Combined B-and T-cell immunodeficiency 145
Chloramphenicol 263 Combined factor V & VIII deficiency 105, 111
Chloramphenicol ointment 187 Common pathway 36
Common variable immunodeficiency 146, 152
Compatibility testing 235

Index 335

Complement deficiency 146 Cord blood stem cell 261
Complementation group analysis 137 Cordocentesis 31
Complete blood count 9, 30, 60, 61, 79, 97, Corpus callosum agenesis 316, 317
Corpus luteum 193, 197
115, 123, 147, 168, 198, 216, 221, 298, Corticosteroid 62, 64, 97, 212, 243, 261
299, 302, 306, 308, 312, 316 Cortisol 254
Complete compatibility testing 238 Coumadin 232
Complete gene deletion 37 COX-2 inhibitor 47
Complete loss 282 Creutzfeldt-Jakob disease 41
Complete resolution 216 Crosslinked fibrin 106
Complete response 58 Crossmatch-compatible platelet 242
Compound heterozygous 7, 108, 289 Crossmatching 236, 237
Computed tomography 47, 64, 79, 213, 214, 229 Cryo-removed plasma 111
Computed tomography arteriography 213, 229 Cryoprecipitate 38, 40, 110, 113, 240, 241,
Computed tomography pulmonary angiography 213, 214
Computed tomography venography 213 302, 303
Conception 280 Cryptogenic stroke 227
Concizumab 45 Culture medium 41
Concrete operation 273 Curettage 85
Conditioning regimen 258, 260, 263 Cutaneous delayed type hypersensitivity 149, 159
Congenital amegakaryocytic thrombocytopenia 97, Cyclic neutropenia 136, 146
136, 138, 139, 316 Cyclophosphamide 172, 263
Congenital defects of phagocyte numbers function 146 Cyclosporine 66, 263
Congenital heart disease 232 Cytogenetic 279
Congenital hemangioma 78, 86 Cytokine 97, 243
Congenital neutropenia 155, 156 Cytomegalovirus 60, 237, 260
Congenital pure red cell aplasia 137 Cytoplasm 91
Congenital thrombophilia 211 Cytosine arabinoside 172
Congestive heart failure 168 Cytoskeleton 96
Conjugated equine estrogen 206
Conjugated estrogen 207, 251 D
Conservative substitution 281 D-dimer 84
Consumptive coagulopathy 77 Dalton 36
Contact factor 111 Danazol 204
Continuous intravenous infusion 13 Dapsone 66
Contractile 91 DDAVP 99, 101
Contracture 47 DDAVP challenge test 99
Coping 270, 274 Deep vein thrombosis 6, 212, 214
Cord blood donor 259 Defect in thymus development 159

336 Index

Defect of innate immunity 146 Dihydrorhodamine 149, 300
Defect of respiratory burst 156 Dihydrorhodamine flow cytometry test 300, 301
Defective platelet aggregation 93 Dilute Russellûs viper venom time 309
Defects in heme biosynthesis 167 Direct antiglobulin test 236, 310
Deferasirox 13, 15 Direct DNA sequencing 283, 289, 292
Deferiprone 13, 15 Direct mutation analysis 283, 285, 286
Deferoxamine 12, 15, 250 Discoid rash 310
Dehydration 229 Disease of immune dysregulation 146
Delayed hemolytic transfusion reaction 242 Disorder of platelet adhesion 93
Deletion 5, 35 Disorder of platelet aggregation 93
Deletion α-thalassemia 30, 290 Disorders of platelet granules 94
Deletional Hb H disease 28, 291 Dispersible tablet 14, 15
Dementia 174 Disseminated tuberculosis infection 300
Denaturing gradient gel electrophoresis 286 Disseminated intravascular coagulation 60, 115,
Dendritic cells 80
Denial 270 212, 215, 240
Dense tubular system 92 Disseminated molluscum contagiosum 160
Dense-granule 91, 96, 99 Distal convoluted tubule 306
Dental loss 139 Distal renal tubular acidosis 306
Deoxygenated 283 Divalent metal transporter1 166
Depot testosterone enanthate 251 DNA polymerase 284
Depot-medroxyprogesterone acetate 206 Dohle-like body 96, 98
Depression 270 Donor 258, 262
Developmental delay 139, 317 Donor lymphocyte infusion 260
Dexamethasone 65 Donor red cell 242
Diabetes mellitus 249, 253 Doppler ultrasound 86, 213
Diagnostic confirmation 279 Double negative T cell 161
Dialysis 172 Down syndrome 227
Diamond- Blackfan anemia 135, 136, 137, 138 Dual-energy x-ray absorptiometry 252
Diepoxybutane 137 Duodenum 165
Differentiation 16, 257 Duplication 286
Difficult child 273 Dysfibrinogenemia 110
Diffuse neonatal hemangiomatosis 77 Dysfunctional uterine bleeding 196, 309
Diffusion-weighted imaging 228 Dysgammaglobulinemia 161
Digeorge syndrome 146, 149, 151 Dyskeratosis congenita 136, 139
Dihydrofolate 171 Dysprothrombinemia 112
Dihydrofolate reductase 171 Dystrophic nail 139

Index 337
Epilepsy 287
E Epinephrine 93, 98
Early megakaryopoiesis 317 Episodic treatment 43
Early treatment 38 Epistaxis scoring system 184
Easy child 273 Epithelioid hemangioendothelioma 85
Ecchymosis 316 Epithelioid hemangioma 79
Echocardiography 227, 229, 262 Epstein syndrome 95, 96
Eczema 96 Erythematous patch 77
EF Bartûs disease 29 Erythrocyte membrane protein 4.2 121, 124
Eftrenonacog alfa 42 Erythroderma 151
EGF-like domain 110 Erythroid hyperplasia 170
Electrocauterization 186 Erythroid progenitor cell 25
Electrolyte 298, 306, 312 Erythropoiesis 5, 252
Electron microscopy 98 Erythropoietic activity 166
Elemental iron 169 Escherichia coli 156
Elicit 275 Esophageal stricture 139
Elliptical-shaped, RBC 122 Esthesioneuroblastoma 183
Eltrombopag 66 Estradiol 192, 205
Embolization 86 Estrogen 192
Embryonic 23 Estrogen breakthrough bleeding 196
Emergency 238 Estrogen withdrawal bleeding 197
Emicizumab 46 Etanercept 261
Empowerment 275 Ethambutol 300
Encapsulated bacteria 124, 161 Ethinyl estradiol 205, 251
Encapsulated organism 66 Evans syndrome 61
Encephalitis 227 Ex vivo gene therapy 265
Endometrial hyperplasia 198 Exchange transfusion 129, 305
Endometrial polyp 196, 198 Exclusive breast feeding 299, 300
Endometrium 193 Exfoliative dermatitis 172
Endoscope 187 Exocrine pancreatic dysfunction 138
Endothelial cell 86, 93 Exponential amplification 284
Engraftment 257, 260 Extended half-life factor concentrate 41
Enoxaparin 216, 219 External carotid artery 227
Enterocyte 166 External genital malformation 77
Enterovirus 152 Extracorporeal membrane oxygenation 239
Enzyme dihydrofolate reductase 171 Extramedullary hematopoiesis 5
Enzymopathy 312 Extravascular hemolysis 121, 236
Eosinophil 148 Extrinsic pathway 105
Eosinophilia 151 Exudative ascites 300
Eye anomalies 77

338 Index

F Fechtner syndrome 95
F V concentrate 107, 112 Ferric iron 12
F X concentrate 111 Ferrioxamine 12
F8 gene rearrangement 37 Ferritin 12, 14, 165, 168, 170
Fabry disease 228 Ferroportin 18, 166
Factor inhibitor 309 Fibrin 105
Factor concentrate 38 Fibrin degradation product 84
Factor I deficiency 105 Fibrinogen 84, 92, 93, 94, 98, 109, 110, 216, 240
Factor IX 266 Fibrinogen disorders 109
Factor IX deficiency 266 Fibrinolytic inhibitor 94
Factor V 94 Fibromuscular dysplasia 227
Factor V deficiency 299 Film-coated tablet 14, 15
Factor V leiden 211 First-line treatment 65, 68
Factor VII deficiency 105, 108 Fitusiran 45
Factor VIII 35 Flanking intronic regions 287
Factor VIII deficiency 266 Flow cytometry 93, 124, 149, 306
Factor VIII level 305 Flu-like syndrome 63, 80
Factor VIII/IX inhibitor 43 Fluorescent spot test 130
Factor VIIIa 80 Folate riched- food 175
Factor X deficiency 105, 299 Foley catheter 187
Factor XI deficiency 105, 111 Folic acid 124
Factor XII 105 Follicular phase 193, 196
Factor XIII deficiency 105, 113 Follicular stimulating hormone 191
Factor XIIIa 80 Foramen lacerum 85
Failure to thrive 138, 151, 316 Formal operation 273
Familial erythrocytosis 282 Frameshift mutation 3, 5, 97, 280, 281
Familial hemophagocytic lymphohistiocytosis 160 Frank iron deficiency anemia 168
Familial Mediterranean fever 146 Free erythrocyte portoporphyrin 168
Fanconi anemia 135, 136, 137, 138 Free thyroxine 251
FAS-pathway apoptosis 161 Fresh frozen plasma 38, 107, 221, 239, 299, 303
Fasting glucose 254 Fulminant infectious mononucleosis 161
Fasting insulin 254 Functional hemoglobin 2, 24, 27
Fat-soluble vitamin 138 Functional iron deficiency 170
Fava beans 127 Furosemide 241
Febrile neutropenia 138 FVIII concentrate 112
Febrile non-hemolytic transfusion reaction 11,

237, 239, 243

Index 339

G Glycoprotein Ib 93
G6PD deficiency 66, 126 Gold standard 159, 213, 228, 230
G6PD level 312 GP Ib/IX/V 92
Gall stone 6 GP IIb/IIIa 92
Gastrectomy 173 Graft rejection 260, 263
Gastrointestinal bleeding 37 Graft-versus-host disease 151, 260
GATA-2 deficiency 146 Gram negative bacteria 156
Gel electrophoresis 288, 290, 313 Granule 91
Gelfoam 187 Granule defect 98, 99
Gene deletion 37 Granulocyte 243
Gene insertion 37 Granulocyte colony-stimulating factor 137
Gene inversion 292 Granulocyte transfusion 157
Gene mutation 280 Gray platelet syndrome 91, 94
Gene therapy 16, 46, 97, 263 Griscelli syndrome 95, 160
Generation sequencing 122 Growth retardation 136, 249
Genetic modifiers 9, 33, 280
Genotype-phenotype correlation 121, 122, 123, H
Haemophilus influenza 152
124, 128, 280, 289, 291, 292, 294, 314 Half-life 36, 41, 42, 108, 111, 113, 114, 215,
Genotypic diagnosis 1
Germline mosaicism 280 216, 241
Germline mutation 280 Haploidentical hematopoietic stem cell transplantation
Giant band neutrophils 174
Giant intracellular granule 148 151, 262, 263
Giant platelet 93 Haptocorrin 171
Giardia lamblia 152 Hb Bartûs hydrops fetalis 23, 24, 27, 31, 33
Glanzmannûs thrombasthenia 93, 184 Hb Constant Spring 23, 25, 28
Global developmental delay 316 Hb H disease 27, 290
Globin 1 Hb H disease with β-thalassemia trait 313
Glucose-6-phosphate 127 Hb Pakse 27
Glucose-6-phosphate dehydrogenase 119, 126, 127 Hb Quong Sze 27
Glutathione 126, 127 Heavy chain 36, 110
Glutathione disulfide 127 Hemangioma 73, 75, 77, 80, 183
Glutathione metabolism 126 Hemangiomatosis 77
Glycogen 91 Hematocrit 236
Glycolipid 91 Hematologic response 176
Glycolysis 126 Hematopoiesis 135
Glycophorin C 119 Hematopoietic stem cell transplantation 16, 151, 257
Glycoprotein 91 Heme 1
Hemihypertrophy 78

340 Index

Hemoglobin contracted cell 130 High responder 43
Hemoglobin 1 High titer 43
Hemoglobin leakage cell 127, 130, 131 High-dose methylprednisolone 63
Hemoglobin typing 31, 312, 313 High-dry heating 40
Hemoglobinopathy 119, 282, 312 Highly purified plasma-derived factor VIII
Hemoglobinuria 241, 242
Hemolysis 25, 64, 306 concentrate 41
Hemolytic anemia 159 HLA matching 243
Hemolytic crisis 32, 121 HLA-matched sibling donor 262
Hemolytic transfusion reaction 12, 241 HLA-matched unrelated donor 262
Hemolytic uremic syndrome 60 Hodgkinûs lymphoma 137
Hemophagocytic lymphohistocytosis 95 Home-based care 38
Hemophilia A 291 Homocysteine 171, 172, 175
Hemophilia B leyden phenotype 37 Homocystinuria 228
Hemophilus influenza type B 148 Homozygous 313
Hemorrhagic stroke 225 Homozygous Hb CS 31
Hemosiderin 165 Homozygous missense mutation 97
Heparin induced thrombocytopenia 216 Homozygous Southeast Asian deletion 27
Heparin resistance 215 Horizontal interaction 120
Hepatic vascular malformation 79 Hospital-based replacement therapy 38
Hepatitis A virus 41 Hoyeraal-Hreidarsson (HH) syndrome 139
Hepatitis B virus 41 Human albumin 41
Hepatitis C virus 41 Human immunodeficiency virus 41, 61
Hepatoblastoma 78, 79 Human leukocyte antigen class I 242
Hepatocyte 165 Human leukocyte antigen 258
Hepcidin 16, 18, 166 Human papilloma virus 160
Hereditary elliptocytosis 120, 122, 123 Hydrogen peroxide 127
Hereditary hemorrhagic telangiectasia 183 Hydrops fetalis 122
Hereditary ovalocytosis 123 Hydroxyurea 16, 172
Hereditary pyropoikilocytosis 123 Hyper IgM syndrome 153, 154
Hereditary spherocytosis 119, 120, 121, 122, 123 Hypertransfusion 262
Hermansky-Pudlak syndrome type 2 160 Hyperhomocysteinemia 174
Herpes simplex 160 Hyper-IgE syndrome 146, 148, 160
Heterozygous 313 Hypercalciuria 252
Hexose monophosphate pathway 130 Hypercoagulable state 6, 227
High flow 78, 86 Hypergonadotropic hypogonadism 250, 251
High molecular weight kininogen 107 Hypermenorrhea 308
High performance liquid chromatography 10 Hypermetabolism 6
Hyperpigmentation 174

Index 341

Hypersegmented neutrophil 175 Impair fasting glucose 253
Hypersplenism 5, 7 Impair glucose tolerance 253
Hypertelorism 159 Imperforate anus 77
Hypochromia 9, 168 In vitro fertilization 18
Hypofibrinogenemia 84, 109 In vivo gene therapy 264
Hypogammaglobulinemia 151, 161 In vivo test 149
Hypogonadism 139, 249, 250 Inclusion body 27, 29, 31, 95, 314
Hypogonadotropic hypogonadism 250, 251 Indirect antiglobulin test 236
Hypoparathyroidism 159, 249, 251 Indirect method 285
Hypoprothrombinemia 112 Ineffective erythropoiesis 5, 6, 16, 25, 27
Hypothalamus 191 Ineffective thrombopoiesis 59, 96
Hypothyroidism 251 Infantile hemangioma 75, 77, 80, 81, 84
Hypotonic solution 123 Infantile hepatic hemangioma 79
Hysterectomy 200 Infectious mononucleosis 60
Hysteroscopy 198 Inferior antrostomy 180
Inferior meatus 180
I Inflammatory bowel disease 159
Infliximab 261
Ibuprofen 200 Inframe deletion 280
Idiopathic thrombocytopenic purpura 57 Infratemporal fossa 85
IgA deficiency 63 Infusion pump 13
IgG subclass deficiency 146, 153 Inherited bone marrow failure syndrome 136,
IgG subclass 148, 154
IgG trough 154 257, 287
IgG3 subclass deficiency 153 Inherited hemolytic anemia 119, 131
Immobilization 212 Inherited platelet disorder 99, 101
Immune 242 Inherited thrombocytopenia 95, 316
Immune thrombocytopenia 57, 152, 183, 242 Inhibitor 37, 41, 107
Immune thrombocytopenic purpura 57 Initiation phase 106, 107
Immune tolerance induction 44 Initiativity 270
Immune-mediated hemolysis 241 Innate immunity 155
Immune-mediated platelet refractoriness 242 Insertion 35, 280, 286
Immunohistochemistry 80 Insulin stimulation test 254
Immunodeficiency 85, 96, 139 Insulin-like growth factor 193
Immunoglobulin 44, 148, 300 Intelligence quotient 175
Immunoglobulin G 63 Interferon 80, 157
Immunohistochemical endothelial marker 75 Internal carotid artery 227
Immunosuppressive drug 66, 85 Internal maxillary artery 180
International normalized ratio 220, 221

342 Index

Interrupted aortic arch 159 J
Intracardiac septal defect 227 Jacobson syndrome 317
Intracellular iron enzymes 170 Joint deformation 47
Intracellular transport (ERGIC-53) pathway 111 Juvenile nasopharyngeal† angiofibroma 85
Intracranial hemorrhage 37, 47
Intralesional corticosteroid 80 K
Intranasal spray 99 Kaposi sarcoma 85
Intrauterine growth retardation 129 Kaposiform hemangioendothelioma 81
Intrauterine transfusion 27 Kasabach-Merritt syndrome 60, 78, 83
Intravascular coagulopathy 86 Kiesselbachûs plexus 180, 181
Intravascular hemolysis 235, 312, 313 Kilodalton 36
Intravenous immunoglobulin 62, 63, 151 Klebsiella spp. 156
Intravenous route 99 Koilonychias 168
Intrinsic factor 171, 173 Kostmann syndrome 146, 156
Intrinsic pathway 105, 303 Krebûs cycle 172
Intron 1 inversion 292
Intron 22 inversion 35, 37, 292 L
Intron mutation 2 L-asparaginase 229
Inversion intron 22 43 L-asparaginase 212, 230
Involuted phase 78 L-thyroxine 251
IRAK4 deficiency 146 Labile cellular iron 12
Iron chelation 12, 289 Lactate dehydrogenase 130
Iron deficiency anemia 165 Lacy reticular skin pigmentation 139
Iron deficient 168 Large deletion 5, 25, 37, 43, 286, 290
Iron depletion 168 Large-scale rearrangement 282
Iron metabolism and absorption 165 Laser therapy 81
Iron overload 6, 12 Late-stage erythropoiesis 16
Iron supplement 169, 170 Lateral nasal wall 179
Iron-enriched food 167, 170 Lateral sinus 229
Iron-fortified formula 170 Lateral spine radiography 250, 254
Iron-refractory iron deficiency anemia 170 Lead poisoning 165, 170
Irreversible aggregation 92 Leftward deletion 290
Irritable bowel disease 170 Lentivirus 265
Ischemic stroke 225, 226 Leukapheresis 259
Isohemagglutinin 148 Leukocyte filtration 237
Isolated thrombocytopenia 57, 61, 63, 91 Leukocyte adhesion defect 146, 156
Isoniazid 300 Leukocyte depleted packed red cell 11, 237, 260, 262
Itraconazole 157

Index 343

Leukocyte poor packed red cell 11, 239, 260, 262 M
Leukocyte removed by centrifugation 239
Leukothrombi 243 Macrocytic anemia 171, 175
LH surge 192, 193 Macrophage 157, 165
Life- threatening 62, 119 Macrothrombocytopenia 95, 98
Light chain 36, 110 Magnesium 252, 254
Linkage analysis 283 Magnetic resonance angiography 79, 229
Lipid bilayer 119 Magnetic resonance arteriography 213
Lipid enveloped 41 Magnetic resonance imaging 12, 43, 79, 213, 228, 316
Lipofuscin 95 Magnetic resonance venography 213, 230
Lipoprotein(a) 211, 214 Major surgery 99, 101
Littleûs area 180, 181 Malabsorption 113, 152, 172, 300
Live attenuated vaccine 57 Malar rash 308, 310, 311
Liver function test 262, 299, 306, 312 Male meiosis 292
Liver hemangioma 78 Malignant 75
Liver iron concentration 13 Malignant lymphoma 183
Locally aggressive 75 Malignant transformation 79
Loss of complete response 58 Massive parallel sequencing 287
Loss of response 58 Massive PE 216
Low pressure liquid chromatography 10 Massive transfusion 237, 240
Low density lipoprotein receptor-related protein 42 Matched- related donor 137, 138
Low flow 86 Maternal T cell 150
Low molecular weight heparin 216, 219, 230 Matrix 91
Low responder 43 Maturation arrest 140
Low titer 43 Maxillary sinus 180
Lupus anticoagulant 212, 309 May-Hegglin anomaly 95
Luspatercept 16 Mean corpuscular hemoglobin 7, 10, 28, 30
Luteal phase 193 Mean corpuscular hemoglobin concentration 123, 130
Luteinizing hormone 191 Mean corpuscular volume 7, 10, 28, 30, 123, 130
Lymphatic tumor 86 Mean fluorescent intensity 307
Lymphoblast 60 Mean platelet volume 158
Lymphocyte 149, 157 Meatus 179
Lymphocyte proliferation 149, 159 Mediastinum 84
Lymphopenia 96, 147 Medical intervention 280
Lymphoproliferation 161 Medroxyprogesterone acetate 205
Lymphoproliferative syndrome 95, 152, 161 Mefenamic acid 200
Lyophilized cryoprecipitate 40 Megakaryocyte 59, 60, 61, 63, 91, 96,
Lysosomal enzyme 156
Lysosomal trafficking regulator 160 97, 139, 140
Lysosome 91, 94, 161

344 Index

Megaloblastic anemia 165, 170, 171, 172, 174, Missense mutation 37, 129, 281
175, 176 Missense variant 127
Mitochondria 91
Megaloblastic dyspoiesis 171 Mitomycin C 137
Megaloblastoid change of erythroid series 174 Mixed malformation 86
Melanin 94, 161 Mixing test 107, 309
Melanophilin 95 Mobile application 200
Melanosome 161 Molecular cytogenetic 279
Membrane attack complex 161 Molecular genetic diagnosis 119
Membrane transport dysfunction 120 Molecular genetic testing 279, 287, 294
Mendelian disorder 279 Monoclonal antibody 66
Mendelian susceptibility to mycobacterial disease Monocyte 157
Monophasic 205
146, 157 Monotherapy 14
Menorrhagia 195 Morbidity 280
Menses 191 Mortality 280
Mercaptopurine 172 Motor development 170
Metabolism of folate 171 Moyamoya disease 227, 232
Metaphyseal dysostosis 138 Mucopolysaccharide 91
Methemoglobinemia 66 Mucosal leukoplakia 139
Methionine 171 Mucous membrane 112
Methotrexate 171, 172 Multifocal 77, 83
Methylmalonic acid 175 Multifocal liver hemangioma 78
Methylprednisolone 84, 261 Multilineage cytopenia 138
Metrorrhagia 195 Multimeric protein 283
Metrorrhagia amenorrhea 196 Multimerin-1 94
MHC class I deficiency 146 Multiplex gap-PCR 313
MHC class II deficiency 146 Multiplex-ligation probe amplification 283, 286, 291
Microangiopathic hemolytic anemia 79 Musculoskeletal complication 47
Microbillirubin 305 Mutation 23, 37, 282
Microcephaly 136 Mutation analysis 137, 283
Microcytic anemia 168 Mutation type 285
Micronized estradiol 207 Myeloblast 60
Micronized progesterone 205, 206 Myelodysplastic syndrome 136, 137, 138, 139, 140
Microperoxisome 91 Myelofibrosis 94
Middle meatus 180 Myeloproliferative disorder 94
Midparental height 250 Myeoloid precursor 140
Minihepcidin 18 MYH-9 related disorders 95, 98
Minor surgery 99, 101 Myoma uteri 196, 198
Minor blood group 11

Index 345

N Nonmuscle myosin heavy chain-A 96
Nanofiltration 40, 41 Nonsense mutation 3, 37, 97, 281, 300
Naproxen 204 Nonsteroidal anti-inflammatory drugs 183, 200
Nasal continuous positive airway pressure 183 Norethindrone acetate 205, 206
Nasal papilloma 183 Norgestrol 205
Nasal septum 179, 180 Normocellular marrow 140
Nasolacrimal duct obstruction 180 Novel deletion 291
Nasopharyngeal plexus 180, 182 Novel gene 287
Nasopharynx 85 Novel mutation 108, 128
National Hemophilia Organization of Thailand 35, 105 Novel property 282
Natural history 279 Nuclear maturation defect 171
Neonatal Fc receptor 42 Nuclear-cytoplasmic asynchrony 171, 174
Neonatal thrombocytopenia 315 Nucleotide 127
Nephritis 95
Nephrotic syndrome 230 O
Neurofibromatosis 227
Neutropenia 14, 138, 148, 152, 155, 161 Obligate carrier 49, 50
Neutrophil 95, 96, 140, 148, 155, 161 Occasional transfusion 11
Neutrophil differentiation 155 Oculocutaneous albinism 94, 161
Newly diagnosed ITP 57 Oligomenorrhea 195
Next generation sequencing 123, 124, 129, 130, Omenn syndrome 150, 151
Open canalicular system 92
287, 293 Opioid 47
Nicotinamide adenine dinucleotide phosphate 127 Opportunistic infection 151
Nitric oxide 6 Opsonization 161
Nitroblue tetrazolium test 149 Oral anticoagulant 216, 230
Nocardia spp 156 Oral glucose tolerance test 253, 254
Non transferrin bound iron 166 Organelle zone 91
Non-deletional α-thalassemia 25, 27, 30, 290 Organism 146
Non-deletional Hb H disease 28, 291 Osmotic fragility test 121, 122, 123
Non-Hodgkin lymphoma 153 Ossification 47
Non-involuting congenital hemangioma 78 Osteocalcin 253
Non-rhabdomyosarcoma 85 Osteogenesis imperfecta 283
Non-scaring alopecia 310 Osteomeatal complex 180
Non-sepsis DIC 215 Osteopenia 249, 252
Non-syndromic 77 Osteoporosis 5, 139, 249, 252, 253
Non-transfusion-dependent thalassemia 11, 15, 33 Osteosarcoma 137
Nonacog beta pegol 42 Ovalocyte 306
Nonfunctional mRNA 3

346 Index

Overt diabetes 253 Pernicious anemia 173, 174, 175
Overt hypothyroidism 251 Perpendicular plate 180
Ovulation 192, 193 Persistent ITP 57
Ovulatory DUB 196, 204 Persistent jaundice 127
Oxidative stress 126, 131 Pesaro classification 261
Oxidized cellulose 187 Petechiae 58, 59
Oxygen free radical 156 PHACES syndrome 77
Oxygen transport 283 Phagocyte 145, 146
Oxymetazoline 186 Phagocyte oxidase 156
Oxymetholone 137 Phagocytic defect 300
Phagolysosome 161
P Phagosome 161
Packed red cell 236 Phenotype 146, 149
Pancreatic enzyme 138 Phenylephrine 186
Pancreatic insufficiency 173 Phosphate 166, 252, 253, 254
Pancytopenia 136, 171, 174, 175, 263 Phosphoenolpyruvic acid 127
Papule 85 Phosphoglycerate kinase deficiency 126
Paracetamol 11, 12, 243, 245 Phospholipid 36
Parathyroid hormone 252, 253 Phospholipid expression 99
Partial resolution 216 Phytohemagglutinin 149
Partially involuting congenital hemangiom 78 Piagetûs cognitive development 273
Parvovirus B19 41, 121 Pica 168
Passive maternal IgG 153 Pictorial blood assessment chart 198
Pasteurization 40 Pigment stone 6
Patent foramen ovale 227, 229 Pituitary gland 250
Pegylation 42 Plant phytates 166
PELVIS syndrome 77 Plasma 40
Penicillin 33, 66 Plasma exchange 44
Penicillin prophylaxis 124 Plasma membrane 92, 95
Percentile 249 Plasma-based 211
Pericarditis 310 Plasma-derived factor 41, 44, 45
Perineal hemangioma 77 Plasmin 216
Peripheral blood 259 Plasminogen 204, 216
Peripheral blood collection 258 Plateau phase 78
Peripheral blood smear 9, 97, 123, 130, 161, 168 Platelet 98, 107
Peripheral hemolysis 6, 27 Platelet factor 4 94
Peripheral neuropathy 174 Platelet adhesion 92
Peripheral zone 91 Platelet aggregation 92, 94, 95, 97, 99, 187

Index 347

Platelet aggregation test 98 Posterior epistaxis 180, 182, 187
Platelet antibody 57 Posterior fossa malformations 77
Platelet antibody screening 315 Posterior nasal packing 187
Platelet apheresis 243 Postmenopausal osteoporosis 16
Platelet concentrate 241 Pre-operational period 273
Platelet dysfunction 96, 196 Pre-symptomatic 279, 294
Platelet flow cytometry 95, 99 Prednisolone 4, 62, 63, 65, 80, 84, 85, 137, 261
Platelet granule 91 Predominantly antibody deficiency 146
Platelet granule deficiency 98 Pregnancy test 198
Platelet procoagulant activity 95 Preimplantation genetic diagnosis 50, 279, 294
Platelet receptor IIb/IIIa 93 Prekallikrein 107
Platelet secretion 92 Premature hair graying 139
Pleuritis 310 Premature termination codon 280
Plica lacrimalis 180 Premenstrual syndromes 196
Pneumatocele 160 Prenatal diagnosis 18, 50, 279, 294
Pneumococcal conjugate vaccine 124, 155 Prenatal growth retardation 139
Pneumococcal polysaccharide vaccine 33, 66, 148 Preparative regimen 258
Pneumocystis jiroveci pneumonia 151 Primary hemostasis 183
Poikilocytosis 123, 168 Primary prophylaxis 42
Point mutation 35, 37, 93, 281, 286, 288, 292, 293 Primary alloimmunization 241
Polycystic ovarian syndrome 197 Primary amenorrhea 251
Polycythemia 227 Primary hypothyroidism 249, 251
Polymenorrhea 195 Primary immunodeficiency disease 145
Polymerase chain reaction 283 Primary immunodeficiency treatment consortium 149
Polymorphism 9 Primary ITP 57
Polymyxin B 187 Primer annealing 284
Polypeptide 1, 5 Prion 41
Polysaccharide 215 Procoagulant activity 99
Polysaccharide antigen 158 Procoagulant drug 229
Polyvinyl alcohol 187 Progesterone 192
Poor wound healing 113 Progesterone breakthrough bleeding 197, 207
Population screening 280 Progesterone withdrawal bleeding 197, 205
Portal fibrosis 261 Progesterone-releasing intrauterine device 204
Possible carrier 50 Progestin 205, 310
Post infectious thrombocytopenia 57 Prognosis 123, 279
Post- traumatic stress disorder 271 Proliferating phase 77
Post-varicella arteriopathy 227 Proliferation 16
Posterior ethmoid sinus 180 Promethazine 207

348 Index

Promotor region 2 Purpura 59
Propagation 45 Purpura fulminans 215
Propagation phase 107 Pyoderma gangrenosum 152
Prophylactic anticoagulant 230 Pyogenic granuloma 85
Prophylactic therapy 42, 43 Pyrazinamide 300
Prophylaxis 109 Pyrimethamine 172
Proplatelet formation 59 Pyruvate kinase 126
Propranolol 79, 84 Pyruvate kinase deficiency 129
Protamine sulfate 215
Protein 4.1R 122 Q
Protein 4.2 121 Quantitative G6PD enzyme assay 130
Protein C 211, 214, 215, 216, 227, 232 Quantitative pancreatic stimulation test 138
Protein C deficiency 227
Protein losing enteropathy 145 R
Protein S 211, 214, 215, 216, 232 Racing car sign 316
Protein S deficiency 227 Radial ray defect 136
Prothrombinase 45 Random platelet 239
Prothrombin 36, 105, 106, 110, 112, 113 Randomized controlled trial 42, 63
Prothrombin complex concentrate 113 Rapidly involuting congenital hemangioma 78
Prothrombin deficiency 112 Rare inherited coagulation disorders 105
Prothrombin mutation G20210A 214 RBC enzymopathy 119
Prothrombin time 107, 115 RBC folate 176
Prothrombinase complex 92, 95 RBC membranopathy 119, 124
Prothrombotic disorder 229 Receptor defect 99
Prothrombotic state 6 Recipient 258
Proton pump inhibitors 174 Recombinant factor 41
Proximal ileum 171 Recombinant factor VIII 44
Proximal jejunum 171 Recombinant factor VIIa 99, 108
Pseudogene 23 Recurrent VTE 215
Pseudothrombocytopenia 97 Recurrent angioedema 161
Pseudotumor 5 Recurrent epistaxis 302
Psychosis 310 Red blood cell distribution width 123, 130
Puff of smoke 227 Red cell antigen typing 242
Pulmonary edema 243 Red cell indices 10, 30, 123
Pulmonary embolism 6, 212, 213, 214 Refractory ITP 58
Pulmonary fibrosis 95, 139 Regression 174
Pulmonary function test 262 Regular transfusion 11, 12, 28, 33
Pulsed methylprednisolone 64 Rehearse 275

Index 349

Renal vein thrombosis 212 Secondary ITP 57
Replacement therapy 107, 108 Secondary Moyamoya 227
Respiratory mucosa 180 Secondary prophylaxis 42, 48
Response 58 Secondary sex characteristics 251
Restriction endonuclease digestion 283, 286 Secondary thrombocytopenia 57
Reticulocyte hemoglobin content 168 Secretion defect 96
Reticulocyte count 122, 130, 170, 175, 306 Secretory phase 193
Reticuloendothelial 5, 62, 63, 215 Selective COX-2 inhibitor 204
Retroperitoneum 84 Selective IgA deficiency 146, 148, 153, 154
Retrovirus 265 Self-renewal 257
Rh D typing 235 Semisolid food 170
Rh-associated glycoprotein 119 Sensitivity 61, 124, 200, 213, 279, 307
Rhabdomyosarcoma 183 Sensorineural hearing loss 95
Rheumatic heart disease 227 Septal cartilage 180
Rhinosinusitis 183 Septal deviation 183
Rhodamine 149 Septal perforation 183, 187
Rifampicin 300 Serotonin 91, 94
Rightward deletion 290 Serotype 154
Ristocetin 93, 98 Serratia marcescens 156
Ristocetin induced platelet aggregation 38 Serum folate 176
Rituximab 44, 66 Serum iron 168
Romiplostim 66 Serum vitamin B12 176
RUNX1 317 Severe combined immunodeficiency 146, 147, 149,
Ruxolitinib 16
150, 151
S Severe congenital neutropenia 136, 140, 146, 157
Saddle nose 159 Severe hemophilia A 266
Saline infusion sonohysterography 198 Severe hemophilia B 266
Salmonella spp. 156 Severe ITP 58
Sanger sequencing 286, 287 Sex determination 50
Scoliosis 139 Shedding 197
Scoring system 157 Sholh solution 306
Scott syndrome 95, 99 Short bowel syndrome 173
SDS-polyacrylamide gel electrophoresis 121 Short philtrum 159
Sebastian syndrome 95 Short stature 249
Second-line treatment 65, 68, 80, 84 Shwachman-Diamond syndrome 135, 136, 138
Secondary hemostasis 183 Sickle cell disease 227, 232
Secondary amenorrhea 251 Signal peptide 36
Signal transduction defect 99

350 Index

Signaling pathway 16 Sphenopalatine artery 180
Single cytopenia 138 Spherical-shaped, RBC 121
Single donor platelet 236, 239 Spherocyte 310
Single gene disorder 23 Spinal cord 6
Single lineage failure 136 Spindle cell hemangioma 79
Single-strand conformation polymorphism 286 Splenectomy 33, 65, 66, 68, 121, 123, 124, 159
Sinonasal cavity 85 Splice junction mutation 2
Sinusitis 180 Splice-site consensus sequence mutation 2
Sirolimus 84, 86 Spontaneous bleeding 42
Skeletal abnormality 138 Sporadic 140
Skin tags 77 Squamous cell carcinoma 139
Slow to warm up child 273 Stability 112
Small deletion 37, 286, 292 Stabilizer 41
Small lymphocyte 93 Stages of grief 270
Small platelet 96 Standard karyotyping 279
Small rearrangement 280 Staphylococcus aureus 156, 160
Smooth and beefy tongue 174 Starch 166
Soft tissue tumor 85 Steatorrhea 138
Sol-gel zone 91 Stem cell rescue 258
Solid tumor 136, 139 Sternal clefts 77
Solitary 81 Stop codon 25
Solute carrier family 4 member 1 121, 124 Storage organelle 92
Solvent/ detergent 40, 41 Storage pool deficiency 96
Somatic mosaicism 280 Strabismus 80
Sotatercept 16 Straight sinus 229
Southeast Asian Ovalocytosis 306 Strawberry hemangioma 73, 77
Southeast Asian Ovalocytosis (SAO) with distal Streptococcus pneumoniae 124, 152
Streptokinase 216
RTA 307 Stroke 225
Southern blot analysis 291 Stromal cell 136
Southern blot hybridization 283 Subclinical hypothyroidism 251
Specific antibody 148 Subcutaneous fat 77
Specific antibody deficiency 146, 148, 154 Subcutaneous injection 80
Specificity 61, 124, 200, 213, 307 Subcutaneous mass 83
Spectrin 119, 123 Subcutaneous route 99
Spectrin alpha erythrocytic 1 121, 124 Subgaleal hemorrhage 37
Spectrin beta erythrocytic 121, 124 Subunit A 113
Spectrin-based cytoskeleton network 120 Subunit B 113
Sphenoid sinus 85

Index 351

Sucrose 41 Termination codon mutation 25
Superior sagittal sinus 229 Tertiary care 217
Superior labial artery 180 Testosterone 192
Superior meatus 180 Tetanus toxoid 149
Superior vena cava syndrome 212 Tetrahydrofolate 171
Superoxide 149 Tetralogy of Fallot 159
Supratrochlear artery 180 Tetramerization 122
Supraumbilical raphe 77 TF-factor VIIa complex 105
Surgical decompression 230 Thalassemia 287
Surgicel 187 Thalassemia facies 5, 11
Surveillance 279 Thalassemia intermedia 7
Symmetrical SGA 315 Thalassemia major 6, 289
Symptomatic 279 Thalassemia syndromes 1
Syndrome with immunodeficiency 146 Thalassemia trait 23
Syndromic 77 The Canadian Pediatric Ischemic Stroke Registry 229
Synovium 47 The International Working Group 57
Syrup 13 The World Health Organization 127
Systemic lupus erythematosus 38, 57, 145, 227, 311 Theta cell 306
Systemic t-PA infusion 221 THI IgG subclass deficiency 154
Thrombocytosis 227
T Thrombophilia testing 214
T cell 145 Thrombin 36, 45, 98, 105, 106, 110
T cell proliferation 151 Thrombin generation 46
T cell receptor 161 Thrombin time 107, 115
T lymphocyte 260 Thrombocytopenia 96
T-cell receptor excision circles 151 Thrombocytopenia with absent radii 97, 136, 140, 316
Tablet 13 Thromboembolism 211, 217
Tampon 200 Thrombolytic agent 216, 230
Tanner staging 251, 254 Thrombophilia 215, 230
Tannin 166 Thrombopoietin 97, 139
Target cell 9, 312 Thrombopoietin receptor agonist 66
Target joint 42, 43 Thrombotic thrombocytopenic purpura 60
Targeted gene panel 287 Thymus 148
Telangiectasia 77 Thymus transplantation 159
Telomere 23, 139 Thyroid hormone 198
Temperament 272 Thyroid stimulating hormone 251
Terminal 161 Tinzaparin 216, 219
Terminal ileum 171, 173 Tissue factor 105, 107

352 Index

Tissue factor pathway inhibitor 45 Unfractionated heparin 215, 218, 221, 230
Tissue factor-VIIa complex 111 Unilateral nasal obstruction 85
Tissue plasminogen activator 216, 221 Unprovoked VTE 215
Topical decongestant 186 Unrelated donor 259
Topical nasal steroid 182 Unstable hemoglobin 32
TORCH titer 315 Upper extremity 212
TPO receptor 138 Upper to lower segment ratio 250, 254
Trabecular bone 252 Urea solubility test 113
Tranexamic acid 99, 101, 109, 111, 204, 310 Uremia 240
Transaminitis 13, 14 Urgency 238
Transcriptional mutation 282 Urine calcium 252, 253, 254
Transferrin 166 Urokinase 216
Transferrin saturation 168 Urticaria 161
Transfusion-associated graft-versus-host disease 237
Transfusion-dependent thalassemia 11, 15, 33 V
Transfusion-related acute lung injury 243
Transient cerebral arteriopathy 227 Valve of hasner 180
Transient hypogammaglobulinemia of infancy 146, 153 Valvular heart disease 227
Transient inhibitor 43 Varicella zoster 227
Transmembrane protease serine 6 (TMPRSS6) 18 Vascular disease 6
Transmission EM 98 Vascular endothelial growth factor receptor-3 80
Triamcinolone acetonide 80 Vascular malformation 73, 75, 86
Trimethoprim/sulfamethoxazole 151, 154, 157, 160 Vascular tumor 73, 75, 86
Trinucleotide repeat expansion 280 Vasculitis 159, 227, 232
Triphalangeal thumbs 137 Vaseline gauze 187
Trisomy 21 151 Vector 265
Trust 269, 275 Venous thromboembolism 215
Tuberculosis peritonitis 300 Ventilation/perfusion scan 213, 214
Tuffed angioma 73, 81 Ventricular septal defect 159
Tumor embolization 85 Vertebral fracture 250
Vertical interaction 120, 121
U Vesicorenal malformation 77
Ultrasound 31 Vincristine 66, 81, 84
Umbilical cord blood 259 Vitamin D 252
Umbilical stump bleeding 113 Vitamin K epoxide reductase 216
Umbilical vein 259 Vitamin K reductase 216
Undescended testes 139 Vitamin K-dependent factor 36, 112
Unequal crossover 25 Vitiligo 174

Index 353

Volume overload 40, 109, 112, 113, 239 X
Von Willebrand disease 38, 198, 303, 304 X-linked agammaglobulinemia 147, 152, 154
Von Willebrand factor 36, 38, 80, 93, 107, X-linked hyper-IgM syndrome 154, 155
X-linked lymphoproliferative disease 161
183, 240, 305 X-linked neutropenia 157
X-linked recessive 49, 50, 96, 97, 126,
W
Warfarin 220, 240 131, 137, 139, 279, 291, 303
Weak organic acid 113 X-linked thrombocytopenia 157
Wet purpura 64
Whole blood 40, 236 Y
Whole exome sequencing 287
Whole gene deletion 282 Yolk sac 135
Whole genome sequencing 287
Whole mount EM 99 Z
Wiskott-Aldrich syndrome 60, 96, 97, 146, 157
Woodruffûs plexus 180, 182 Zinc 250, 254
World Health Organization bleeding score 184, 200

¥—™π’

° °“√¢“¥À“¬¢π“¥„À≠à 25, 290
°–‚À≈°»√’…– 5 °“√¢“¥À“¬¢Õ߬π’ α-globin 25, 30
°“√‡°‘¥ªØ‘°‘√‘¬“¿Ÿ¡‘·æ‡â ©¬’∫æ≈—π√πÿ·√ß 37 °“√¢“¥À“¬¢Õ߬’π α2-globin 25
°“√·∑√°‡æ‘¡Ë 35 °“√¢“¥À“¬·∫∫„À¡à 291
°“√ —߇§√“–Àå FVIII 36 °“√¢“¥À“¬™π¥‘ Southeast Asian (--SEA) type 25
°“√°≈“¬æπ—∏‚åÿ¥¬µ√ß 285 °“√¢“¥À“¬™π¥‘ Thai (--THAI) type 25
°“√ √â“ß “¬‚ª√µπ’ 9 °“√¢“¥À“¬‰ª¢Õß∑—È߬’π 282
°“√ √â“ß “¬‚ª√µ’π α-globin 30 °“√¢“¥ÕÕ°´‡‘®π 27, 165, 187
°“√ √“â ß “¬‚ª√µ’π β-globin 30 °“√¢¬“¬µ«—¢Õ߉¢°√–¥°Ÿ 5, 252
°“√ √“â ß·Õπµ‘∫Õ¥’µàÕ‡°≈Á¥‡≈Õ◊ ¥ 57 °“√¢π àß«‘µ“¡π‘∫1’2 173
°“√ √“â ߧ«“¡‰««â “ß„® 275 °“√¢Ÿ¥¡¥≈Ÿ° 207
°“√ √“â ß·ø§‡µÕ√å 35 °“√¥”‡ππ‘‚√§ 154, 279
°“√ √â“ߌÕ√‚å ¡π 6 °√¥Õ–¡‘‚π 1, 25, 36, 288, 290
°“√ ≈—∫¥“â π¢Õ߬’π 292 °“√¥Ÿ¥´÷¡∏“µÿ‡À≈Á° 165
°“√‰À≈‡«¬’π¢Õ߇≈◊Õ¥‡√Á« 78 °“√¥Ÿ·≈√—°…“∑’∫Ë“â π 38
°“√ àÕß°≈Õâ ß 187 °“√¥·Ÿ≈ºŸâªÉ«¬‚√§Œ’‚¡ø‡ï ≈¬’ 50
°“√ àÕß°≈âÕßµ√«®¿“¬„π‚æ√ß¡¥≈Ÿ° 198 °“√©¥’ “√Õÿ¥À≈Õ¥‡≈Õ◊ ¥·¥ß 187
°√–¥Ÿ°§¥ 139 °“√©“¬√ß— ’85, 152, 159, 160, 237, 258
°√–¥Ÿ°·¢Áß 180 °“√¬π◊ ¬—π°“√«π‘‘®©¬—‚√§ 294
°√–¥°Ÿ∫“ß 252 °“√®—∫°≈àÿ¡°π—¢Õ߇°≈Á¥‡≈◊Õ¥ 92, 94
°√–¥°Ÿæ√πÿ 249, 252 °“√°√–®“¬·∫∫‡ªìπ‡ πâ µ√ß 77
°√–¥Ÿ°º‘¥√ªŸ 5 °“√°√–µÿâπ¢Õ߇°≈Á¥‡≈◊Õ¥ 92
°√–¥Ÿ°ÕàÕπ 180 °“√°≈“¬æπ—∏ÿå 2, 4, 5, 7, 8, 25, 26, 37, 93, 95, 96,
°√–∫«π°“√„π°“√ª√—∫µ«— 270
°√–∫«π°“√ ß—‡§√“–Àå°≈µŸ“‰∏‚Õπ 126 108, 121, 122, 124, 127, 131, 138-140, 157, 160,
°√–∫«π°“√ √“â ߇¡¥Á‡≈Õ◊ ¥ 135 167, 170, 281, 282, 283, 285, 286, 288, 289, 290,
°√–∫«π°“√ √â“߇´≈≈ å ∫◊ æ—π∏ÿå¢Õ߇滙“¬ 292 300, 306, 313
°√–∫«π°“√¥¥Ÿ´÷¡¢Õ߇À≈Á° 6 °“√°≈“¬æ—π∏å¢ÿ𓥇≈Á° 280
°√–∫«π°“√·¢ßÁµ—«¢Õ߇≈Õ◊ ¥ 45 °“√°≈“¬æ—π∏ÿå¢π“¥„À≠à 282
°√–∫«π°“√≈¥®”π«π‡¡¥Á‡≈Õ◊ ¥¢“« 11 °“√°≈“¬æπ—∏å¢ÿÕ߬’π β-globin 28
°√–‡æ“–Õ“À“√ 173 °“√°≈“¬æ—π∏åÿ¢Õ߇∫µ“â -∏“≈ —´’‡¡’¬ 5
°“√¡°’Õâ πÀ≈“¬µ”·Àπßà 83 °“√°≈“¬æ—π∏¢åÿÕß‚√§·Õ≈øÉ“-∏“≈ —´’‡¡¬’ 25, 27
°“√¡‡’≈Õ◊ ¥ÕÕ°®“°·º≈µ¥— “¬ –¥Õ◊ 113 °“√°≈“¬æ—π∏™åÿ𑥄À¡à 108
°“√¡Õ߇ÀπÁº¥‘ª°µ‘13 °“√°≈“¬æπ—∏ÿ∑å ’¡Ë’·µ°à ”‡π¥‘ 280
°“√¢“¥∏“µÿ‡À≈Á° 170 °“√°≈“¬æ—π∏åÿ∑‡Ë’°¥‘¢πÈ÷„π¿“¬À≈—ß 280
°“√¢“¥‚ø‡≈µ 171, 175 °“√°≈“¬æπ—∏ÿ凩擖∑’Ë2, 35, 281, 288, 292, 293
°“√µ¥—¡¥≈Ÿ° 205

320 ¥™— π’

°“√µ¥—¡“â ¡ 7, 33, 61, 64, 66, 67, 121, 124, 126 °“√µ√«®√–¥∫—Õ≥Ÿæπ—∏ÿ»“ µ√å 300
°“√µ—¥°√–‡æ“–Õ“À“√ 173 °“√µ√«®«‡‘§√“–À™å π‘¥¢Õߌ‚’¡‚°≈∫π‘ 31
°“√µ¥—∂ÿßπ”È¥’126 °“√µ√«®«‡‘§√“–Àå≈”¥∫—𑫧≈’‚Õ‰∑¥å 293
°“√µ‘¥µàÕ Ë◊Õ “√„π·Õªæ≈‡‘§™π—ˉ≈π°å ≈ÿà¡ 40 °“√µ√«®‚§√‚¡‚´¡«∏‘’¡“µ√∞“π 279
°“√µ‘¥‡™◊ÈÕ 28 °“√µ√«®‚æ√ß®¡°Ÿ 181
°“√µ¥‘‡™ÕÈ◊ «—≥‚√§ 300 °“√µ√«®‰¢°√–¥°Ÿ 60, 61
°“√µ‘¥‡™Õ◊È©«¬‚Õ°“  151 °“√µ√«®À“°“√°≈“¬æπ—∏ÿå¢Õ߬’π 283
°“√µ‘¥‡™◊ÕÈ∑Ë√’πÿ·√ß®π∂÷ß·°™à ’«µ‘ 151 °“√µ√«®À“°“√°≈“¬æπ—∏‚ÿå ¥¬µ√ß 283
°“√µ‘¥‡™ÕÈ◊ ∑Ë’º«‘Àπ—ß 155 °“√µ√«®À“æ“À– 48, 49
°“√µ¥‘‡™◊ÈÕ∫√‘‡«≥ à«π»√’…–·≈–≈”§Õ 229 °“√µ√«®À“æ“À–‚√§Œ‚’¡øï‡≈¬’ 49
°“√µ¥‘‡™ÕÈ◊ √“ 260 °“√µ√«®æ“À–¢Õß‚√§ 294
°“√µ¥‘‡™ÕÈ◊ √–∫∫∑“߇¥‘πÀ“¬„® 155 °“√µÕà √Õß 270
°“√µ¥‘‡™◊ÈÕ„π™È—π„µºâ ‘«Àπ—ß 145 °“√µÕ∫ πÕß 66, 154, 170, 175
°“√µ‘¥‡™ÕÈ◊ „πªÕ¥ 145 °“√µÕ∫ πÕߢÕ߇°≈¥Á‡≈Õ◊ ¥ 63
°“√µ¥‘‡™ÕÈ◊ „πÀ™Ÿ—Èπ°≈“ß 145 °“√·¢ßÁµ—«¢Õ߇≈◊Õ¥ 6, 105
°“√µ‘¥‡™◊ÈÕ‰«√—  57, 260 °“√·¢ßÁµ«—¢Õ߇≈◊Õ¥∑ºË’¥‘ª°µ‘60
°“√µ‘¥‡™ÈÕ◊ À≈—ß°“√µ¥—¡â“¡ 124 °“√·µ°¢Õ߇¡¥Á‡≈Õ◊ ¥·¥ß„πÀ≈Õ¥‡≈◊Õ¥ 235
°“√µ°‰¢à 198 °“√·µ°¢Õ߇¡Á¥‡≈◊Õ¥·¥ß 126
°“√µ√«® Õ∫‰«√— ∑Ë·’¡πà ¬” 41 °“√·µ°¢Õ߇¡Á¥‡≈◊Õ¥·¥ßπÕ°À≈Õ¥‡≈◊Õ¥ 121, 236
°“√µ√«®«—¥ª√‘¡“≥‡Õπ‰´¡å G6PD 130 °“√·∑√°‡æ¡‘Ë 280
°“√µ√«®§¥—°√Õß 121 °“√·∑âß∫ÿµ√ 110
°“√µ√«®§«“¡‡¢“â °—π‰¥â 235, 236 °“√·ºàµ«—ÕÕ° 92
°“√µ√«®§«“¡º‘¥ª°µ‘∑“ßæ—π∏°ÿ√√¡ 149 °√≥’¥«à π 238
°“√µ√«®¬◊π¬π—°“√°≈“¬æ—π∏åÿ108 °√≥¥’«à π¡“° 238
°“√µ√«®°√Õß°“√°≈“¬æ—π∏åÿ286 °√≥’©ÿ°‡©π‘ 238
°“√µ√«®™È‘π‡πÕÈ◊ 80 °√≥’ª°µ‘238
°“√µ√«®∑“ß√—ß ’«∑‘¬“ 84, 299 °“√∂“à ¬∑Õ¥·∫∫¬π’¥Õâ ¬∫π‚§√‚¡‚´¡∏√√¡¥“ 279
°“√µ√«®∑“ßæπ—∏°ÿ√√¡ 293, 294 °“√∂“à ¬∑Õ¥∑“ßæ—π∏°ÿ√√¡ 23, 131
°“√µ√«®∑“ß欓∏«‘∑‘¬“ 75 °“√∂“à ¬∑Õ¥∫π‚§√‚¡‚´¡ 105
°“√µ√«®∑“ßÀÕâ ߪؑ∫—µ‘°“√ 61, 79, 101, 176, 299 °“√∂“à ¬∑Õ¥µ“¡°Æ¢Õ߇¡π‡¥≈ 279
°“√µ√«®∑“ßÕ≥Ÿ-‡´≈≈æå —π∏»ÿ“ µ√å 279 °“√∂“à ¬‡≈Õ◊ ¥ 129, 241
°“√µ√«®∑“ßÕ≥柗π∏ÿ»“ µ√å 279, 314 °“√∑∫∑«π 275
°“√µ√«®∑“ßÕâÕ¡ 283, 285 °“√∑√ßµ«—∑º’Ë¥‘ª°µ‘139
°“√µ√«®«π‘®‘©—¬°àÕπ¡’°“√Ωíßµ«—¢Õßµ—«ÕàÕπ 279 °“√∑”≈“¬‡°≈Á¥‡≈◊Õ¥‚¥¬°≈‰°∑“ßÕ¡‘¡Ÿπ 66
°“√µ√«®«π‘®‘©¬—°Õà π¡Õ’“°“√ 294 °“√∑”ß“π¢Õßµ∫—ÕàÕπ∑º’Ë¥‘ª°µ‘138
°“√µ√«®«π‘‘®©¬—°àÕπ§≈Õ¥ 31, 279 °“√∑”ß“π¢Õ߇¡Á¥‡≈◊Õ¥∑º’Ë¥‘ª°µ‘257
°“√µ√«®«π‘®‘©—¬™π‘¥¢Õß‚√§·Õ≈øÉ“-∏“≈ —´‡’¡’¬ 30 °“√∑”ß“π¢Õ߇°≈¥Á‡≈Õ◊ ¥ 198
°“√µ√«®√–¥—∫‡À≈Á° 12 °“√∑”ß“π¢Õ߉µº¥‘ª°µ‘14

¥™— π’ 321

°“√«‘π®‘©—¬°Õà π§≈Õ¥ 294 °“√„™âÀà«ß§ÿ¡°”‡π‘¥∑Ë’¡‚’ª√‡® µ‘π 205
°“√«‘π®‘©¬—°Õà π°“√Ωíßµ—«¢Õßµ«—ÕÕà π 294 °“√„À⧔ª√÷°…“·π–π”∑“ßæ—π∏»ÿ“ µ√å 48, 49
°“√«‘π‘®©—¬∑“√°„π§√√¿°å Õà π§≈Õ¥ 18 °“√„À·â ø§‡µÕ√∑å ¥·∑π 108
°“√«π‘®‘©¬—∑“ßÀâÕߪØ∫‘µ—°‘“√ 38 °“√„À‡â °≈¥Á‡≈Õ◊ ¥ 64, 65, 97, 139, 159
°“√«π‘®‘©—¬‚√§ 60, 67 °“√„À‡â ≈◊Õ¥ 11, 289, 306
°“√«‘π‘®©—¬‚√§°àÕπ§≈Õ¥ 48 °“√„Àâ‡≈Õ◊ ¥·≈– «à πª√–°Õ∫¢Õ߇≈◊Õ¥ 235
°“√«π‘®‘©¬—„π√–¥∫—‚¡‡≈°ÿ≈ 50 °“√„Àâ‡≈Õ◊ ¥‡ªìπ§√—Èߧ√“« 11
°“√«‘π‘®©—¬æ“À–¢Õß‚√§ 294 °“√„Àâ‡≈Õ◊ ¥„π°√≥‡’≈Õ◊ ¥®“߇©’¬∫æ≈—π 32
°“√∫—π∑÷°¢âÕ¡≈Ÿ 275 °“√„Àâ‡≈◊Õ¥„π°√≥‡’≈Õ◊ ¥®“߇√ÕÈ◊ √—ß 33
°“√√–§“¬‡§Õ◊ ß°√–‡æ“–Õ“À“√ 170 °“√„À‡â ≈◊Õ¥„π‚√§·Õ≈øÉ“-∏“≈— ´‡’¡¬’ 32
°“√√—°…“¡“µ√∞“π 64 °“√„À‡â ≈Õ◊ ¥À√Õ◊  «à πª√–°Õ∫¢Õ߇≈◊Õ¥ 160
°“√√°—…“¥â«¬¬π’∫”∫¥— 46, 264 °“√‰¥â¬‘π∑’ºË¥‘ª°µ‘95
°“√√°—…“°“√¢“¥∏“µ‡ÿÀ≈Á° 170 °“√‰À≈‡«’¬π‡≈Õ◊ ¥™â“ 86
°“√√—°…“·∫∫ª√–§—∫ª√–§Õß 32 °“√‰À≈‡«’¬π‡≈Õ◊ ¥‡√«Á 86
°“√√—°…“‚√§Œ’‚¡ø‡ï ≈¬’ 38 °“√À¥µ—«¢Õß≈‘Ë¡‡≈Õ◊ ¥ 98
°“√√°—…“Õ“°“√‡≈Õ◊ ¥ÕÕ°„π√“¬∑¡Ë’ ’“√µ“â π·ø§‡µÕ√å 44 °“√À¬¥ÿ √â“ß‚ª√µ’π 37
°“√≈–≈“¬≈¡Ë‘‡≈Õ◊ ¥·∫∫ ¡∫Ÿ√≥å 216 °“√ª≈àÕ¬ “√‡§¡’„π‡°≈Á¥‡≈Õ◊ ¥ 92
°“√≈“â ߉µ 172 °“√À≈ß≈◊¡ 174
°“√‡¢“â  à«Ÿ¬—Àπ¡ÿà  “« 254 °“√ª≈Ÿ°∂“à ¬‡´≈≈åµπâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥ 16, 97, 137, 139,
°“√‡¥‘πº¥‘ª°µ‘174
°“√‡®√‘≠‡µ‘∫‚µ∑ºË’‘¥ª°µ„‘π§√√¿å 139 149, 151, 155, 159, 257, 258
°“√‡®√‘≠‡µ‘∫‚µ™â“ 6, 249, 250 °“√ª≈°Ÿ∂à“¬‡´≈≈µå â𰔇𑥇¡¥Á‡≈◊Õ¥®“°æπË’âÕß 137, 138
°“√‡®√‘≠‡µ‘∫‚µ∑’ºË‘¥ª°µ‘136 °“√ª≈°Ÿ∂“à ¬‡´≈≈µå πâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥‚¥¬„™‡â ´≈≈µå π‡Õß266
°“√‡®√‘≠‡µ∫‘‚µª°µ‘28 °“√ª≈°Ÿ∂“à ¬‰∑¡ — 159
°“√‡°“–µ¥‘¢Õ߇°≈Á¥‡≈◊Õ¥°∫—À≈Õ¥‡≈Õ◊ ¥ 92 °“√ª≈Ÿ°∂à“¬Õ«¬—«– 212
°“√‡°¥‘ “√µ“â π 309 °“√æ≤— π“¢Õ߇¡¥Á‡≈◊Õ¥¢“« 152
°“√‡°¥‘¿¡Ÿµ‘â“π∑“πµàÕ‡¡Á¥‡≈Õ◊ ¥¢“« 11 °“√æ≤— π“°“√„™·â ø§‡µÕ√‡å ¢â¡¢âπ 40
°“√‡°¥‘≈‘¡Ë‡≈Õ◊ ¥Õÿ¥µπ— 44, 46 °“√欓°√≥‚å √§ 67, 73, 86, 123, 131, 152, 153, 154,
°“√‡°¥‘„À¡‡à ©æ“–∑Ë’85
°“√‡°¥‘æß—º◊¥„πªÕ¥ 139 232, 279
°“√‡Ω“Ñ √–«ß— 131, 279 °“√ªÑÕß°—π‡≈Õ◊ ¥ÕÕ° 42
°“√‡º™≠‘ ª≠í À“ 274 °“√ªØ‘ π∏„‘πÀ≈Õ¥∑¥≈Õß 18
°“√„  à “¬ «πÀ≈Õ¥‡≈◊Õ¥ 101, 211, 2, 12 °“√Õ—°‡ ∫¢Õ߉µ 95
°“√„ à¬π’ 264 °“√Õ°—‡ ∫„π‚æ√ß®¡°Ÿ 182
°“√„™â¬“¢∫—‡À≈Á°√à«¡°π— 14 °“√Õ∏‘∫“¬ 275
°“√„™·â ø§‡µÕ√凢¡â ¢âπ 40 °“√º“à µ¥— 85, 86, 93
°“√„™â√–ß∫—Õ“°“√ª«¥ 47 °“√º“à µ—¥‡¬Ë◊Õ∫®ÿ¡°Ÿ°“√ºà“µ¥—ºπß—°È—π™àÕß®¡Ÿ° 182
°“√„™‚â §‡§π Ÿ¥∑“ß®¡Ÿ° 183 °“√ºà“µ—¥À≈°— 101
°“√Õÿ¥µπ—√®Ÿ¡°Ÿ¢â“߇¥’¬« 85
°“√«“ß·ºπ§√Õ∫§√—« 48, 307

322 ¥™— π’

°≈Õâ ß®≈ÿ∑√√»πÕå ‡‘≈°Áµ√Õπ 91, 95, 98 §«“¡™°ÿ 106, 126, 152, 153, 156, 253
°≈¡ÿà §«“¡º‘¥ª°µ‘¢Õ߇Õπ‰´¡å‡¡¥Á‡≈◊Õ¥·¥ß 126 §«“¡∂Ë¢’Õß°“√¡’‡≈◊Õ¥ÕÕ°„π ¡Õß´È” 47
°≈¡àÿ∑¡Ë’¿’“«–‡°≈Á¥‡≈◊Õ¥µË” 101 §«“¡√πÿ·√ߢÕß¿“«–‡≈Õ◊ ¥ÕÕ° 59
°≈ÿà¡‚√§‰¢°√–¥°ŸΩÕÉ µßÈ—·µ°à ”‡π‘¥ 135, 138, 141 §«“¡√ÿπ·√ߢÕß‚√§ 29, 47, 123
°≈¡àÿ‰¡à¡Õ’“°“√· ¥ß∑“ߧ≈‘π‘° 28 §«“¡√πÿ·√ߢÕß‚√§·Õ≈ø“É -∏“≈— ´’‡¡¬’ 23, 33
°≈ÿà¡Õ“°“√µâ“πøÕ ‚ø≈‘ª¥î 212 §«“¡√πÿ·√ߢÕß‚√§‡∫µ“â -∏“≈ —´’‡¡’¬ 1
°≈ÿ¡à Õ“°“√∑Ë¡’¿’¡Ÿ§‘¡ÿâ °—π∫°æ√Õà ß 146, 157 §«“¡≈÷°¢Õß°âÕπ 77
°≈¡àÿÕ“°“√∏“≈— ´’‡¡’¬ 1 §«“¡≈°÷¢Õß√Õ¬‚√§ 84
°âÕπ‡¥’¬Ë« 81 §«“¡‡ ¬Ë’ß 31, 50
°âÕπ„µâº‘«Àπß— 83 §«“¡‡ ’ˬߵàÕ°“√‡°‘¥‡≈Õ◊ ¥ÕÕ°ß“à ¬‰¥â 216
‡°≈¥Á‡≈◊Õ¥ 36, 38, 57, 63, 64, 66, 91, 95, 106, 157, §«“¡‡ Ë¬’ßµÕà ¿“«–‡≈Õ◊ ¥ÕÕ° 215
§«“¡®”‡æ“– 61, 124, 200
161, 216, 236, 239, 257, 263 §«“¡‰« 61, 124, 200, 279
‡°≈¥Á‡≈◊Õ¥¢π“¥‡≈°Á 96, 98 §«“¡Àπ“·πàπ¢Õß°√–¥Ÿ° 252, 254
‡°≈Á¥‡≈◊Õ¥¢π“¥„À≠à 93, 98 §«“¡æ°‘“√∑“ß ¡Õß 108
‡°≈Á¥‡≈◊Õ¥µË” 60, 96, 157, 159, 239 §«“¡º‘¥ª°µ¢‘Õߺπß—‡¡Á¥‡≈◊Õ¥·¥ß 119
‡°≈¥Á‡≈Õ◊ ¥∑”Àπâ“∑’˺¥‘ª°µ‘96 §«“¡º‘¥ª°µ‡‘™ß‘ª√‘¡“≥ 113
‡°≈¥Á‡≈◊Õ¥‡¢â¡¢πâ 94, 101 §«“¡º‘¥ª°µ‘¢Õ߬’π F8 35
‡°≈¥Á‡≈Õ◊ ¥‡ªìπ ‡’∑“ 91 §«“¡º¥‘ª°µ¢‘Õ߬’π F9 36
‚°≈∫‘π 1 §«“¡º‘¥ª°µ‘¢Õ߬’π‡æ¬’߬’π‡¥¬’« 23
§«“¡º¥‘ª°µ¢‘Õß°√–¥°Ÿ 140
¢ §«“¡º¥‘ª°µ‘¢Õß°√–¥°Ÿ —πÀ≈ß— 250
¢π—ȵÕπ°“√√—°…“¥â«¬¬’π∫”∫¥— 264 §«“¡º‘¥ª°µ¢‘Õß°“√§«∫§ÿ¡¢Õß√–∫∫¿¡Ÿ‘§âÿ¡°—π 58
¢π“¥¢Õ߇°≈Á¥‡≈◊Õ¥ 98 §«“¡º‘¥ª°µ¢‘Õß°“√°≈“¬æ—π∏åÿ37
¢∫«π°“√µâ“π°“√·¢ßÁµ—«¢Õ߇≈Õ◊ ¥ 45 §«“¡º¥‘ª°µ‘¢Õß°“√¶à“‡™ÈÕ◊ ¿“¬„π‡´≈≈å 156
¢∫«π°“√ √“â ߇¡Á¥‡≈◊Õ¥·¥ß∑’‰Ë¡à¡’ª√– ‘∑∏‘¿“æ 5, 27 §«“¡º¥‘ª°µ‘¢Õß°“√·¢ßÁµ«—¢Õ߇≈◊Õ¥ 183, 196
¢Õâ ®”°¥—„π°“√„™·â ø§‡µÕ√凢¡â ¢âπ 43 §«“¡º‘¥ª°µ‘¢Õß°“√∑”ß“π¢Õ߇°≈¥Á‡≈◊Õ¥ 60
¢Õâ æ°‘“√‡√◊ÕÈ√—ß 110 §«“¡º‘¥ª°µ‘¢Õß°“√‡§≈Ë◊Õπ∑’Ë¢Õ߇¡¥Á‡≈Õ◊ ¥¢“« 156
‰¢°√–¥Ÿ° 5, 60, 95, 96, 135, 170, 171, 258 §«“¡º‘¥ª°µ‘¢Õß°“√æ—≤π“¢Õ߇¡Á¥‡≈Õ◊ ¥¢“« 155
§«“¡º‘¥ª°µ‘¢Õß√–∫∫∑“߇¥‘πª í  “«– 137
§ §«“¡º‘¥ª°µ‘¢Õß√–∫∫‡≈◊Õ¥ 226
§«“¡‡ªì𵫗¢Õßµ—«‡Õß 270 §«“¡º‘¥ª°µ‘¢Õ߇¡¥Á‡≈Õ◊ ¥¢“« 152
§«“¡º‘¥ª°µ¢‘ÕßÀ≈Õ¥‡≈Õ◊ ¥ 229 §«“¡º‘¥ª°µ¢‘Õ߇≈∫Á 139
§«“¡¥—π‡≈◊Õ¥µ”Ë 240, 241, 243 §«“¡º‘¥ª°µ¢‘Õß‚ª√µπ’∑ºË’πß—‡¡Á¥‡≈◊Õ¥·¥ß 121
§«“¡¥—π‚≈Àµ‘ Ÿß 40, 182 §«“¡º‘¥ª°µ‘¢Õ߉µ 136
§«“¡¬“«™à«ß≈”µ—«°—∫™«à ߢ“ 250 §«“¡º‘¥ª°µ¢‘Õßªí®®—¬°“√·¢ßÁµ—«¢Õ߇≈Õ◊ ¥ 299
§«“¡°√–®à“ߢÕߢÕâ ¡Ÿ≈ 275 §«“¡º¥‘ª°µ‘¢ÕßÀ—«„® 226
§«“¡·¡πà ¬” 215
§«“¡·√ߢÕß “√µâ“π·ø§‡µÕ√å 43

¥™— π’ 323

§«“¡º‘¥ª°µ¢‘ÕßÀ≈Õ¥‡≈Õ◊ ¥∑Ë—«√à“ß°“¬ 183 ®
§«“¡º¥‘ª°µ¢‘Õßøíπ 139 ®¡Ÿ°°«â“ß 160
§«“¡º¥‘ª°µ‘¢Õߺπ—߇¡¥Á‡≈◊Õ¥·¥ß 120, 121, 122 ®”π«π‡°≈¥Á‡≈◊Õ¥µË” 60
§«“¡º¥‘ª°µ¢‘Õߺ‘«Àπß— 139 ®È”‡¢¬’« 93
§«“¡º‘¥ª°µ‘∑‡’Ë°¥‘¢È÷π¿“¬À≈—ß 211 ®È”‡≈Õ◊ ¥ 37, 58, 59, 61, 62, 112, 174, 292, 316
§«“¡º‘¥ª°µ∑‘“ßæπ—∏ÿ°√√¡ 141, 150, 211 ®¥ÿ‡≈Õ◊ ¥ÕÕ° 58, 59, 187
§«“¡º‘¥ª°µ‡‘™ß‘§≥ÿ ¿“æ 113
§√÷ßËÀ≈—ߢÕß√Õ∫ª√–®Ì“‡¥◊Õπ 195 ©
§√√¿å‡ªìπæ‘… 32 ©¥’∑“ß„µâº‘«Àπ—ß 45, 216
§≈◊Ëπ·¡‡à À≈Á°‰øøÑ“ 251
§≈Ëπ◊ ‡ ’¬ß§«“¡∂ ’Ëߟ™π¥‘ doppler 213 ™
§“à §«“¡‡¢â¡¢âπ‡≈◊Õ¥ 236
§ÿ≥ ¡∫µ—‘¢Õß·ø§‡µÕ√凢⡢πâ 41 ™°— 252
§≥ÿ ¿“æ¢Õ߇°≈Á¥‡≈Õ◊ ¥ 101 ™π¥‘¢Õߌ’‚¡≈‚°≈∫‘π 29
§ÿ≥¿“晫’µ‘ 40, 50, 101, 249, 269 ™π¥‘√—∫ª√–∑“π 80
·§≈‡´¬’¡ 91, 92, 252, 253 ™π‘¥√πÿ·√ß¡“° 38
‡§√◊ÕËߪπòí ·¬°‡¡Á¥‡≈◊Õ¥Õµ—‚π¡—µ‘259 ™π¥‘√ÿπ·√ßπÕâ ¬ 38
‡§√◊ËÕß™«à ¬©¥’¬“ 13 ™π¥‘√πÿ·√ߪ“π°≈“ß 38
‡§√◊ËÕß«‡‘§√“–À凡¥Á‡≈Õ◊ ¥Õ—µ‚π¡µ—‘10 ™π¥‘‡©¬’∫æ≈—π 57
‚§√‚¡‚´¡ X 35, 36 ™π‘¥‡√È◊Õ√ß— 57
‚§√‚¡‚´¡§Ÿà∑’Ë11 112 ™à«ß«—¬∑“√° 269
‚§√‚¡‚´¡§Ÿà∑’Ë13 110 ™à«ß«—¬√πÿà 270
‚§√‚¡‚´¡§àŸ∑Ë’2 111 ™à«ß«¬—‡¥°Á‡≈°Á 269
‚§√‚¡‚´¡§Ÿ∑à Ë’18 111 ™«à ߇¥Á°«—¬‡√¬’π 270
‚§√‚¡‚´¡§Ÿà∑’Ë1 106 ‡™◊ÈÕ√“ 145
‚§√‚¡‚´¡§∑àŸ’Ë11 1 ‡™ÈÕ◊ ‰«√—  265
‚§√‚¡‚´¡§∑Ÿà Ë’13 108
‚§√‚¡‚´¡§∑àŸË’16 23 ´
‚§√‚¡‚´¡§Ÿà∑Ë’2 9 ´’¥ 60, 261, 305, 306, 307, 308, 310, 311, 312
‚§√‚¡‚´¡§∑àŸË’21 317 ‰´π—  179
‚§√‚¡‚´¡§∑Ÿà Ë’4 109, 111 ‰´π— Õ°—‡ ∫ 145, 153, 180
‚§√‚¡‚´¡§Ÿà∑Ë’6 9 ‰´π— Õ—°‡ ∫¬¥◊ ‡¬È◊Õ 154
‚§√ß √“â ߢÕߧ√Õ∫§√«— 272 ‡´≈≈å ∫◊ æπ—∏åÿ280
‚§√ß √â“ߢÕ߇°≈Á¥‡≈Õ◊ ¥ 91 ‡´≈≈åµâ𰔇𑥇¡Á¥‡≈Õ◊ ¥®“° “¬ –¥Õ◊ √° 261
‚§√ß √â“ߢÕߺπ—߇¡¥Á‡≈◊Õ¥·¥ß 120 ‡´≈≈åµπâ °”‡π‘¥‡¡¥Á‡≈Õ◊ ¥®“°°√–· ‡≈◊Õ¥ 259
‡´≈≈åµâ𰔇𥑇¡Á¥‡≈Õ◊ ¥®“°ºâ„ŸÀ‡â °‘¥ªØ°‘‘√¬‘“µàÕµ“â π 260
‡´≈≈åµπâ °”‡π‘¥‡¡Á¥‡≈Õ◊ ¥∑’Ë„ÀâºâŸª«É ¬‰¡µà ‘¥ 260
‡´≈≈剢¡—π 136
‡´≈≈æå π—∏»ÿ“ µ√å 279
‡´≈≈æå Ë’‡≈Ȭ’ß 136

324 ¥™— π’

¥ ∑àÕπ”ȵ“Õ¥ÿµ—π 180
¥“à ߢ“« 174 ∑Õâ ߇ ¬’‡√Õ◊È√ß— 172
‡¥°Á°≈ÿà¡∑Ë’µâÕß°“√‡«≈“„π°“√ª√—∫µ«— 273 ∑“ßÀ≈Õ¥‡≈Õ◊ ¥¥” 81, 84, 215
‡¥Á°°≈ÿ¡à ‡≈Ȭ’߬“° 273 ‡∑§‚π‚≈¬’42
‡¥°Á°≈¡ÿà ‡≈¬È’ßßà“¬ 273
∏

µ ∏“µÿ —ß°– ’250
µ«—π” 265 ∏“µ‡ÿÀ≈Á° 165, 169
µ∫—¡’æß—º¥◊ 261, 262 ∏“≈— ´‡’¡’¬ 1,266
µ—∫Õ°—‡ ∫ 151
µ∫—ÕàÕπ 173 π
µ«—‡µ’Ȭ 139, 249 ·π«µßÈ— 120
µ—«‡À≈Õ◊ ß 129, 242 ·π«∑“ß°“√√°—…“ 73
µ—«Õ ÿ®‘193 ·π«∑“ß°“√√—°…“¥«â ¬·ø§‡µÕ√‡å ¢¡â ¢âπ 40
µ«—ÕàÕπ¡πÿ…¬å„π§√√¿å 23 ·π«πÕπ 120
µ“¢È‡’°¬’® 80 π¡««— 166, 167, 170, 171
µ“∫Õ¥ ’13 π¡·¡à 166, 167
µ“‡¢ 80 𫑧≈‚’Õ‰∑¥å 5, 37, 289
µàÕ¡πÈ”‡À≈◊Õß 152, 300 π”ȵ“≈°≈‚Ÿ§  253
µÕà ¡π”ȇÀ≈◊ÕßÕ—°‡ ∫ 155, 156 π”ȵ“≈„π‡≈◊Õ¥º‘¥ª°µ‘253
µàÕ¡„µâ ¡Õß 251 π”È∑à«¡ªÕ¥ 243
µàÕ¡„µ â ¡Õß à«πÀπâ“ 191 π”ȇ°≈◊Õæπà ®¡Ÿ° 189
µÕà ¡‰∑¡—  159 π«Ë‘„π∂ßÿπ”È¥’6, 126
µÕâ °√–®° 95 π«È‘À—«·¡à¡Õ◊ º‘¥√Ÿª 137
µ‘Ë߇πÈ◊Õ‡¬Õ◊Ë∫ÿ‚æ√ß¡¥≈Ÿ° 196 ‡π◊ÕÈßÕ°„π®¡Ÿ°™π¥‘·æ∫æ≈‘‚≈¡“ 183
‰µ«“¬ 40 ‡πÕÈ◊ ßÕ°¡¥≈Ÿ° 196
‡π◊ÈÕßÕ°¢ÕßÀ≈Õ¥‡≈Õ◊ ¥ 73, 75, 183
∂ ‡π◊ÈÕßÕ°„π‚æ√ßÀ≈ß—®¡Ÿ° 182

∂«—˪“°Õâ“ 127 ∫
∂¥∂Õ¬ 174 ·∫∫°Õâ π‡¥Ë¬’« 77
∂ßÿπÈ”¥’6 ·∫∫‡ªπì  «à π 77
∂ÿ߉¢à·¥ß 135 ·∫∫À≈“¬°Õâ π 77
∫√‡‘«≥ºπ—ß°π—È®¡°Ÿ¥“â πÀπâ“ 181
∑ ‡∫µâ“-∏“≈— ´’‡¡¬’ 1, 6
∑“√°§≈Õ¥§√∫°”Àπ¥ 165 ‡∫π´π‘ 263
∑“√°§≈Õ¥°Õà π°”Àπ¥ 166, 167, 217
∑“√°·√°‡°‘¥ 225, 239

¥™— π’ 325

ª º“â °Õ´™ÿ∫«“ ≈‘π¡«â π 187
·ªÑß “≈’166 ºŸâ ßŸÕ“¬ÿ172
‚ª√µπ’ FVIII 36 º∫âŸ√‘®“§‡´≈≈µå â𰔇𥑇¡¥Á‡≈◊Õ¥ 258, 259
‚ª√µ’πµâ“π°“√·¢ßÁµ—«¢Õ߇≈◊Õ¥ 216 ºªâŸ«É ¬·Õ≈ø“É -∏“≈ —´’‡¡’¬ 11
‚ª√µ’π∑’§Ë«∫§ÿ¡‡°¬Ë’«°—∫‡À≈°Á 18 ºŸâª«É ¬∑’Ë¡’¿Ÿ¡§‘¡âÿ°π—∫°æ√àÕß 85
‚ª√µ’π∫πºπß—‡¡¥Á‡≈◊Õ¥·¥ß 121 ºŸâªÉ«¬∑‰Ë’¥√â —∫‡≈◊Õ¥‡ªìπª√–®” 249
‚ª√‡® µπ‘ 207 ºªâŸÉ«¬∏“≈— ´‡’¡¬’∑Ë’¡’‡À≈Á°‡°‘π¡“°„πµ∫—·≈–„πÀ«—„® 14
‚ª√‡® ‡µÕ‚√π 193 ºªŸâ «É ¬‚√§À«—„®™π¥‘‡¢’¬« 227
ª√– ‘∑∏‘¿“æ¢Õß·ø§‡µÕ√凢⡢âπ 41 ºŸâªÉ«¬Œ‚’¡ø‡ï ≈¬’ ‡Õ ∑’¡Ë ’“√µ“â π 46
ª√– “∑À≈Õπ 174 ºâªŸÉ«¬Œ’‚¡øï‡≈’¬ ‡Õ ∑’‰Ë¡¡à ’ “√µ“â π 45, 46
ª√–®”‡¥Õ◊ π¡“¡“° 110, 191, 308, 309 º°—„∫‡¢¬’« 171
ªÕ¥Õ°—‡ ∫ 151, 156
ªØ°‘‘√‘¬“≈°Ÿ‚´à‚æ≈’‡¡Õ‡√  283 Ω
ªØ‡‘ ∏ 270
ªí  “«– ‡’¢¡â 127, 290, 312 Ωï„πªÕ¥ 160
ª í  “«–∫Õà ¬ 253
ªí®®¬—°“√·¢ßÁµ«—¢Õ߇≈◊Õ¥ 37, 105, 239 æ
ªí®®¬—‡ ’¬ËßµàÕ°“√‡°‘¥≈‘Ë¡‡≈Õ◊ ¥Õ¥ÿµ—π‰¥â 212 æ≤— π“°“√™“â 139, 316
ª≠í À“‡≈◊Õ¥®“ß 61 欓∏‘ √√’«∑‘¬“¢Õß‚√§·Õ≈øÉ“-∏“≈— ´’‡¡¬’ 27
ª≠í À“‡≈◊Õ¥°”‡¥“ÕÕ°„π‡¥°Á 179 欓∏‘«‘∑¬“¢ÕßÀ≈Õ¥‡≈◊Õ¥ 73
ªí≠À“‚√§æ—π∏°ÿ√√¡„π§√Õ∫§√«— 48 æ“√“‰∑√Õ¬¥Œå Õ√‚å ¡π 252
ª≠í À“ª√–®”‡¥Õ◊ πÕÕ°¡“°„π«—¬√ÿàπ 310 惵‘°√√¡∑Ë·’ ¥ßÕÕ°¿“¬πÕ° 270
惵‘°√√¡∑‡Ë’°∫Á°¥‰«¿â “¬„π 270
º æ≈“ ¡“ 235, 240, 241, 309
·º≈‡√È◊Õ√ß— 33 æÈ◊πÕ“√¡≥å 272
·º≈À“¬¬“° 156 æ“À–¢Õß∏“≈— ´‡’¡’¬ 18, 23
·º≈À“¬™â“ 155 æ“À–¢Õß‚√§ 279
ºπß—¢â“ß®¡Ÿ° 179 æ“À–¢Õß‚√§Œ‚’¡øï‡≈’¬ 49
ºπ—ߢÕ߇¡Á¥‡≈Õ◊ ¥·¥ß 306 æ“À–·Õ≈øÉ“-∏“≈ —´‡’¡’¬ 9, 23, 31
ºπß—°π—È™Õà ß®¡°Ÿ 179 æ“À–‡∫µ“â -∏“≈ —´’‡¡¬’ 10, 30, 31
º≈¢â“߇§’¬ß∑“ß√–∫∫∑“߇¥‘πÕ“À“√ 14 ‚æ√ß®¡Ÿ° 179
º≈°√–∑∫µÕà §ÿ≥¿“æ™’«µ‘ 65, 66 ‚æ√߉¢°√–¥°Ÿ 5
º≈°√–∑∫µÕà ®‘µ„® 270 ‚æ√ßÀ≈Õ¥‡≈Õ◊ ¥¥”„π ¡ÕßÕ¥ÿµπ— 226, 229, 230
º≈°√–∑∫µàÕµ«—§√Õ∫§√—« 270
º≈°√–∑∫√–¬–¬“« 47 ø
º≈µ‘¿≥— ±‡å ≈Õ◊ ¥ 11 ·ø§‡µÕ√å ‡¢¡â ¢âπ 41, 43, 44, 48, 50
º≈µàÕ ÿ¢¿“段‘„® 32 ·ø§‡µÕ√å I 106, 114
·ø§‡µÕ√å II 106, 112, 114, 299

326 ¥™— π’
¿“«–·∑√°´âÕπ∑“ßµàÕ¡‰√∑â àÕ 249
·ø§‡µÕ√å IX 114, 266, 299, 303 ¿“«–¿¡Ÿ§‘âÿ¡°π—µ”Ë 95
·ø§‡µÕ√å V 106, 114 ¿“«–¿Ÿ¡‘§¡ÿâ °π—∫°æ√àÕß 139
·ø§‡µÕ√å V ‡¢¡â ¢âπ 112 ¿“«–™ÁÕ° 60, 253
·ø§‡µÕ√å VII 106, 108, 109, 114, 299 ¿“«–∑Ë¡’°’“√·¢ßÁµ—«¢Õ߇≈Õ◊ ¥º‘¥ª°µ‘229
·ø§‡µÕ√å VIII 112, 114, 292, 302, 303 ¿“«–∑’‡Ë¡Á¥‡≈◊Õ¥·¥ß·µ° 119
·ø§‡µÕ√å VIII ‡¢¡â ¢âπ 112 ¿“«–∑’ˇªìπ°√¥ 165
·ø§‡µÕ√å X 106, 114, 299 ¿“«–∑âÕߺ°Ÿ 189
·ø§‡µÕ√å X ‡¢â¡¢âπ 111 ¿“«–∑’˺ŸâªÉ«¬¡’¿Ÿ¡§‘¡ÿâ °—πµÕà øÕ ‚ø≈ª‘î¥ 38
·ø§‡µÕ√å XI 106, 114 ¿“«–∑ÿæ≈¿“æ 47
·ø§‡µÕ√å XIII 106, 114 ¿“«–∑ÿæ‚¿™π“°“√ 138
¿“«–πÈ”µ“≈µË” 81
¿ ¿“«–≈¡Ë‘‡≈Õ◊ ¥Õ¥ÿµ—π 172, 205, 211
¿“«–º¥‘ª°µ‘¢Õ߇°≈¥Á‡≈Õ◊ ¥·µ°à ”‡π‘¥ 316 ¿“«–≈¡Ë‘‡≈◊Õ¥Õ¥ÿµ—π„π ¡Õß 212
¿“«– –‡∑Õ◊ π¢«≠— À≈ß—‡Àµÿ°“√≥√å πÿ·√ß 271 ¿“«–≈Ë‘¡‡≈◊Õ¥Õÿ¥µ—π„π‚√ß欓∫“≈ 211
¿“«– ¡“∏‘ π—È 42 ¿“«–≈‘¡Ë‡≈◊Õ¥Õÿ¥µπ—„πÀ≈Õ¥‡≈◊Õ¥ 217
¿“«–‡°≈¥Á‡≈◊Õ¥µË” 137 ¿“«–≈‘Ë¡‡≈Õ◊ ¥Õÿ¥µ—π„πÀ≈Õ¥‡≈◊Õ¥¥” 211
¿“«– Ÿ≠‡ ¬’π”È 229 ¿“«–‡¡Á¥‡≈◊Õ¥¢“«µË” 61, 138
¿“«–¢“¥§«“¡‡ªπì °√¥ 173 ¿“«–‡¡¥Á‡≈Õ◊ ¥·¥ß·µ° 64, 131
¿“«–¢“¥«‘µ“¡‘π ∫1’2 174 ¿“«–‡¡¥Á‡≈Õ◊ ¥·¥ß·µ°ß“à ¬º‘¥ª°µ·‘µà°”‡π¥‘ 119
¿“«–¢“¥«µ‘“¡π‘ ‡§ 240, 299 ¿“«–‡§√’¬¥√ÿπ·√ß 253
¿“«–¢“¥·ø§‡µÕ√å V ·µà°”‡π‘¥ 111 ¿“«–‡°≈¥Á‡≈Õ◊ ¥µ”Ë 57, 59, 83, 97, 138, 140, 174
¿“«–¢“¥·ø§‡µÕ√å VII ·µà°”‡π¥‘ 108 ¿“«–‡°≈¥Á‡≈Õ◊ ¥µË”·≈–‡°≈¥Á‡≈◊Õ¥¢π“¥„À≠à 95
¿“«–¢“¥·ø§‡µÕ√å X ·µà°”‡π‘¥ 110 ¿“«–‡≈Õ◊ ¥®“ß 11, 61, 121, 129, 130, 137, 206, 242, 252
¿“«–¢“¥∏“µÿ —ß°– ’254 ¿“«–‡≈Õ◊ ¥®“߇√◊ÕÈ√—ß 6, 16, 129, 249, 252
¿“«–¢“¥π”È 212 ¿“«–‡≈Õ◊ ¥°”‡¥“ÕÕ°´È” 184
¿“«–¢“¥‡À≈°Á 10 ¿“«–‡≈Õ◊ ¥ÕÕ°√ÿπ·√ß 64
¿“«–¢“¥ŒÕ√å‚¡π‰∑√Õ¬¥å 252 ¿“«–‡≈Õ◊ ¥ÕÕ°√πÿ·√ß∑˧’°ÿ§“¡µÕà ™«’‘µ 64
¿“«–§«“¡√ÿπ·√ߢÕ߇≈Õ◊ ¥®“ß 119 ¿“«–‡≈◊Õ¥ÕÕ°„π ¡Õß 47, 108
¿“«–§«“¡¥π—„π ¡Õß Ÿß 230 ¿“«–‡≈Õ◊ ¥ÕÕ°„π ¡Õß„π‚√§Œ’‚¡øï‡≈¬’ 47
¿“«–©°ÿ‡©‘π 44, 151 ¿“«–‡≈Õ◊ ¥ÕÕ°„π‡¥Á° 105
¿“«–°“√‡°¥‘‡≈Õ◊ ¥ÕÕ°„π ¡Õß´”È 48 ¿“«–‡≈Õ◊ ¥ÕÕ°„πÕ«¬—«– ”§≠— 64
¿“«–´’¥ 27, 61, 137, 168, 287, 290 ¿“«–‡≈Õ◊ ¥ÕÕ°À≈ß—®“°°“√„À¬â “ 216
¿“«–µ—«‡µ¬È’ 249, 250 ¿“«–‡≈Õ◊ ¥ÕÕ°ß“à ¬ 35, 158, 189, 239
¿“«–µàÕ¡‰∑√Õ¬¥∑å ”ß“π≈¥≈ß 78 ¿“«–‡≈◊Õ¥ÕÕ°ßà“¬®“°°“√·¢Áßµ—«¢Õ߇≈◊Õ¥·µà°”‡π‘¥ 105
¿“«–µàÕ¡À¡«°‰µ∑”ß“π∫°æ√Õà ß 253 ¿“«–‡À≈Á°‡°π‘ 6, 16, 18, 249, 261
¿“«–·§≈‡´¬’¡„π‡≈Õ◊ ¥µ”Ë 160 ¿“«–‡ªπì Àπàÿ¡ “«™â“ 249
¿“«–·∑√°´âÕπ 43, 78, 79, 84 ¿“«–‚≈Àµ‘®“ß 165, 168, 175

¥™— π’ 327

¿“«–‚≈Àµ‘®“ß®“°°“√¢“¥ “√Õ“À“√ 176 ¬
¿“«–‚≈Àµ‘®“ß®“°°“√¢“¥∏“µÿ‡À≈Á° 165, 168, 170 ¬“¢∫—‡À≈Á° 12, 261, 262, 289
¿“«–‚≈Àµ‘®“ß®“°°“√¢“¥‚ø‡≈µ «µ‘“¡‘π∫’12 165 ¬“¢—∫‡À≈Á°™π¥‘√∫—ª√–∑“π 13
¿“«–‚≈Àµ‘®“ß√«à ¡°—∫‡¡Á¥‡≈Õ◊ ¥¢“« ·≈–‡°≈¥Á‡≈Õ◊ ¥µ”Ë 171 ¬“¢∫—ª í  “«– 32, 241
¿“«–‰µ«“¬ 241 ¬“§ÿ¡°”‡π‘¥ 206, 229
¿“«–‰µ«“¬‡©’¬∫æ≈π— 242 ¬“§ÿ¡°”‡π¥‘™π¥‘©¥’‡¢â“°≈“â ¡ 206
¿“«–À—«„®«“¬ 168, 170, 243, 252 ¬“§¡ÿ°”‡π‘¥™π‘¥ŒÕ√å‚¡π√«¡ 204, 205, 207
¿“«–ª√–®“̇¥Õ◊ πº¥‘ª°µ‘195 ¬“°π—™—° 60, 172
¿“«–À≈Õ¥‡≈Õ◊ ¥ ¡ÕßÕÿ¥µπ— 227 ¬“°¥¿Ÿ¡§‘âÿ¡°π— 260, 263
¿“«–æ√àÕ߉∑√Õ¬¥Œå Õ√‚å ¡π 249 ¬“µ“â π®ÿ≈™’æ 145
¿“«–æ√Õà ßæ“√“‰∑√Õ¬¥åŒÕ√å‚¡π 249, 252 ¬“µâ“π®≈ÿ™æ’™π¥‘ªÑ“¬ 187
¿“«–Õ°—‡ ∫‡√ÕÈ◊ √—ߢÕ߇¬ËÕ◊ ∫ÿsynovium 47 ¬“µâ“π°“√·¢ßÁµ—«¢Õ߇≈◊Õ¥ 215
¿“«–º‘¥ª°µ¢‘Õß¿¡Ÿ§‘âÿ¡°—π∫°æ√àÕß™π¥‘ª∞¡¿Ÿ¡‘302 ¬“µ“â π°“√Õ°—‡ ∫™π¥‘‰¡à„™ à ‡µ¬’√Õ¬¥å 189, 204
¿“«–º‘¥ª°µ¢‘Õ߇¡Á¥‡≈Õ◊ ¥·¥ß·µ°ß“à ¬·µ°à ”‡π¥‘ 312 ¬“∑¬Ë’∫—¬ß—È°“√∑”ß“π¢Õß‚ø‡≈µ 172
¿“«–º‘¥ª°µ‘¢Õ߇°≈¥Á‡≈◊Õ¥·µà°”‡π‘¥ 91 ¬“∑’‰Ë¡„à ™à·ø§‡µÕ√‡å ¢¡â ¢πâ 50
¿“«–º¥‘ª°µ‘¢ÕßÀ≈Õ¥‡≈◊Õ¥·µà°”‡π¥‘ 73, 86 ¬π’¥âÕ¬∫π‚§√‚¡‚´¡‡æ»À≠‘ß 279
¿“«–Õ«â π 197 ¬’π∫”∫—¥ 16, 97, 263
¿“æ∂“à ¬√—ß ’∑√«ßÕ° 148, 151 ¬’π„À¡à 287
¬“√–∫“¬ 189
¡ ¬“≈–≈“¬≈¡Ë‘‡≈Õ◊ ¥ 196, 206
¡–‡√ßÁ 75 ¬“≈¥°√¥ 167
¡–‡√Áß°≈“â ¡‡πÈÕ◊ ≈“¬ 183 ¬“≈¥‰¢â 245
¡–‡√ÁßµÕà ¡π”ȇÀ≈◊Õß 159, 183 ¬“‡§¡’∫”∫¥— 85, 258, 260, 263
¡–‡√ßÁµàÕ¡À¡«°‰µ™π¥‘∑’¡Ëµ’â𰔇𥑄π‚æ√ß®¡Ÿ° 183 ¬“À≈Õ° 11
¡–‡√ßÁ‡¡¥Á‡≈◊Õ¥¢“« 97, 230 ¬µÿ‘°“√µß—ȧ√√¿å 32
¡–‡√Á߇¡Á¥‡≈Õ◊ ¥¢“«‡©¬’∫æ≈π— 136 ‡¬◊ËÕ∫ÿ®¡°Ÿ 179
¡–‡√ßÁ„π®¡Ÿ° 183 ‡¬ÕË◊ ∫ÿ®¡°ŸÕ°—‡ ∫ 181
¡—ß «‘√—µ‘173 ‡¬◊ÕË∫ÿ≈”‰ â 166
¡Õ√øå πï 47 ‡¬ÕË◊ ∫ÿ‚æ√ß¡¥≈°Ÿ 193
¡≈Ÿπ∏‘‚‘√§‡≈Õ◊ ¥ÕÕ°ß“à ¬Œ‚’¡ø‡ï ≈¬’·Àßà ª√–‡∑»‰∑¬ 35, 38, 105 ‡¬ËÕ◊ ∫‚ÿæ√ß¡¥≈Ÿ°‡®√≠‘ º‘¥∑’Ë196
‡¡Á¥‡≈◊Õ¥¢“«µË” 13 ‡¬◊ËÕÀÿâ¡ ¡ÕßÕ—°‡ ∫ 153
‡¡¥Á‡≈Õ◊ ¥·¥ß 6, 27, 257, 263
‡¡¥Á‡≈Õ◊ ¥·¥ß¢π“¥‡≈Á° 312 √
‡¡Á¥‡≈◊Õ¥·¥ß·µ° 127 √–¥—∫¢Õ߇°≈Á¥‡≈◊Õ¥ 61, 64, 65
‡¡Á¥‡≈◊Õ¥·¥ß„π‰¢°√–¥°Ÿ 175 √–¥∫—§«“¡√πÿ·√ß 61
‚¡‡≈°ÿ≈ 42 √–¥—∫§«“¡√πÿ·√ߢÕßÕ“°“√‡≈◊Õ¥ÕÕ° 61, 62, 67
‰¡à¡’Õ“°“√ 109 √–¥∫—§«“¡√ âŸ÷°µ—« 228
√–¥∫—°“√ªÑÕß°—π°“√·¢ßÁµ«—¢Õ߇≈Õ◊ ¥ 105

328 ¥™— π’

√–¥∫—·ø§‡µÕ√å 42, 106 ‚√§‡≈Õ◊ ¥®“ß∏“≈ —´’‡¡’¬ 253
√–¬–¢Õß°“√ª√∫—µ—«°∫—¢à“«√⓬ 270 ‚√§‡≈◊Õ¥ÕÕ°ßà“¬∑“ßæπ—∏°ÿ√√¡ 35, 93, 291, 299
√–¬–∑°Ë’Õâ π¡°’“√‡®√≠‘ ‡µ∫‘‚µ 77 ‚√§‡≈◊Õ¥ÕÕ°ß“à ¬À¬ÿ¥¬“° 113
√–¬–∑’Ë°Õâ π¬ÿ∫≈ß 78 ‚√§‰¢°√–¥°ŸΩÉÕ 60, 97, 135, 138, 184, 263
√–¬–∑°Ë’Õâ π™–≈Õ°“√‡®√≠‘ ‡µ‘∫‚µ 78 ‚√§À—«„®æ‘°“√·µà°”‡π‘¥ 159
√–¬–‡«≈“∑Ë’¡ª’√–®”‡¥◊Õπ 195 ‚√§À≈Õ¥‡≈◊Õ¥ ¡Õß∑‰Ë’¡∑à √“∫ “‡Àµÿ227
√–¬–ªØ‘ π∏‘280 ‚√§À≈Õ¥‡≈◊Õ¥ ¡ÕßÕÿ¥µπ—„π‡¥Á° 232
√–¬“ߧ å «à π≈“à ß 78
√–∫∫‰À≈‡«’¬π‚≈Àµ‘≈¡â ‡À≈« 119 ≈
√—߉¢à 250 ≈°—…≥–¢Õ߬π’ α-globin 29
√Õ¬¥” 174 ≈—°…≥–°“¬«‘¿“§¢Õß‚æ√ß®¡°Ÿ 179
√Õ¬‚√§ 84 ≈°—…≥–°“√°√–®“¬¢Õß°Õâ π 77
√Õ∫ª√–®“̇¥Õ◊ π 191 ≈°—…≥–∑“߇æ»∑µÿ¬‘¿Ÿ¡‘251, 254
√Ÿ‡ªî¥¢Õß∑àÕπ”ȵ“ 180 ≈°—…≥–∑“ßæ—π∏°ÿ√√¡ 1, 23
√Ÿª√“à ߢÕ߇°≈Á¥‡≈Õ◊ ¥ 94 ≈—°…≥–∑“ßæπ—∏°ÿ√√¡·≈–≈—°…≥–∑“ߧ≈‘π°‘ 280, 294
‚√§¡–‡√ßÁ 97 ≈¡Ë‘‡≈Õ◊ ¥Õ¥ÿµ—π„πÀ≈Õ¥‡≈Õ◊ ¥¥” 6, 212
‚√§¡–‡√ßÁ¢ÕßÕ«¬—«–·∫∫∑‡Ë’ªπì °âÕπ 136 ≈‘Ë¡‡≈Õ◊ ¥Õÿ¥µ—π¢π“¥„À≠„à πÀ≈Õ¥‡≈◊Õ¥¥”™È—π≈°÷ 212
‚√§¡–‡√Á߇¡¥Á‡≈Õ◊ ¥¢“« 60 ≈‘Ë¡‡≈Õ◊ ¥Õ¥ÿµ—π∑Ë’À≈Õ¥‡≈◊Õ¥·¥ß„πªÕ¥ 212
‚√§¡–‡√ßÁ„π‡¥°Á 212 ≈‘Ë¡‡≈◊Õ¥Õ¥ÿµ—π„πÀ≈Õ¥‡≈Õ◊ ¥¥”∑ˉ’µ 212
‚√§¡“≈“‡√’¬ 126 ≈Ë¡‘‡≈◊Õ¥Õÿ¥µ—π„πÀ≈Õ¥‡≈Õ◊ ¥·¥ß 212, 230
‚√§¢Õâ Õ°—‡ ∫√Ÿ¡“µÕ¬¥å 161 ‡≈◊Õ¥ÕÕ°„µÀâ πß—»√’…– 37
‚√§¢ÕßµàÕ¡‰∑√Õ¬¥å 198 ‡≈Õ◊ ¥ÕÕ°„π ¡Õß 37, 109, 159, 230
‚√§®¡°ŸÕ—°‡ ∫¿¡Ÿ·‘æâ 183 ‡≈Õ◊ ¥ÕÕ°ßà“¬·µÀà ¬¥ÿ¬“° 35, 37
‚√§·Õ≈ø“É -∏“≈— ´‡’¡’¬ 23, 25, 26, 27, 31, 33 ‡≈Õ◊ ¥®“° “¬ –¥◊Õ√°∑Ë’∫√‘®“§ 259
‚√§¿¡Ÿ‘§¡âÿ°π—µ“â πµπ‡Õß 135, 145 ‡≈◊Õ¥°”‡¥“ÕÕ° 186, 302, 303
‚√§¿Ÿ¡‘§âÿ¡°π—∫°æ√Õà ߪ∞¡¿¡Ÿ‘145, 149, 162 ‡≈◊Õ¥°”‡¥“ÕÕ°®“°¥“â πÀπ“â ¢Õß‚æ√ß®¡Ÿ° 180
‚√§∑¡Ë’§’«“¡º‘¥ª°µ‘¢Õß°“√§«∫§ÿ¡¿Ÿ¡‘§¡âÿ°π— 146 ‡≈◊Õ¥°”‡¥“ÕÕ°®“°¥â“πÀ≈—ߢÕß‚æ√ß®¡°Ÿ 182
‚√§∑¡Ë’§’«“¡º‘¥ª°µ‘¢Õß√–∫∫¿¡Ÿ§‘ÿâ¡°—π∑ˉ’¡à®”‡æ“– 146 ‡≈◊Õ¥‰À≈‰¡àÀ¬ÿ¥À≈ß—®“°°“√¢≈∫‘Àπ—ßÀ¡âÿª≈“¬Õ«¬—«– 37
‚√§∑“ß°√–¥Ÿ° 5 ‡≈◊Õ¥ÕÕ°∑’ Ë–¥◊Õ 109
‚√§∑“ß¿Ÿ¡‘§âÿ¡°—πº¥‘ª°µ‘61 ‡≈Õ◊ ¥ÕÕ°„π√–∫∫∑“߇¥π‘Õ“À“√ 37
‚√§∑“ßæ—π∏°ÿ√√¡ 264, 287 ‡≈Õ◊ ¥ÕÕ°„π‡¬ÕË◊ ∫ÿ58, 60
‚√§∏“≈— ´‡’¡’¬ 6, 166, 168, 170, 249, 250, 253, 269
‚√§≈¡™—° 287 «
‚√§‡°≈Á¥‡≈Õ◊ ¥µ”ˇ√◊ÈÕ√—ß 93 «“ ≈π‘ 189
‚√§‡∫µâ“-∏“≈ —´’‡¡’¬ 1, 4, 9, 16, 18 «—§´π’ 124, 151, 160, 292
‚√§‡∫“À«“π 249, 253 «§—´π’‡™◊ÈÕ‡ªπì 154, 159
‚√§‡√Õ◊È√ß— 269, 271, 272 «§—´’πªÑÕß°—π‚√§‰¢âÀ«—¥„À≠à 155
‚√§‡≈Õ◊ ¥®“ß∑“ßæ—π∏ÿ°√√¡ 1 «—¬‡®√≠‘ æ—π∏åÿ75

¥™— π’ 329

«—¬„°≈Àâ ¡¥ª√–®”‡¥◊Õπ 196 À≈Õ¥‡≈Õ◊ ¥„π ¡Õß·µ° 225
«¬—Àπ¡ÿà  “« 250 À≈Õ¥‡≈◊Õ¥„π ¡ÕßÕÿ¥µ—π 225
«µ‘“¡π‘¥’252, 253 À≈Õ¥‡≈◊Õ¥Õ°—‡ ∫ 227
«µ‘“¡‘π´’170 À≈Õ¥Õ“À“√µ’∫ 139
«µ‘“¡π‘∫1’2 171, 172 À™ŸÈ—π°≈“ßÕ°—‡ ∫ 153
«‘∏°’“√°”®¥—‰«√— ∑Ë’¡§’ÿ≥¿“æ 41
Õ
» ‡Õ ‚µ√‡®π 193, 207
‡Õ°´‡√¬å§Õ¡æ‘«‡µÕ√åÀ≈Õ¥‡≈Õ◊ ¥¥”/·¥ß 213
»√’…–‡≈°Á 136 ‡Õ°´‡√¬å°√–¥Ÿ° π—À≈ß— 250, 254
‡»√“â 270 ‡Õ°´‡√¬Õå “¬ÿ°√–¥Ÿ° 250, 254
‡Õ°≈°—…≥嵫—‡Õß 270
  ·Õπµ∫‘Õ¥’11, 62, 148, 152, 153, 235
·Õπµ‘∫Õ¥µ’àÕ°“√º≈‘µ‡°≈¥Á‡≈◊Õ¥„π‰¢°√–¥°Ÿ 59
 –¥Õ◊ À≈¥ÿ™“â 156 ·Õπµ∫‘Õ¥µ’Õà «§—´π’ 148
 –¥Õ◊ Õ°—‡ ∫ 156 ·Õπµ‘∫Õ¥∑’’®Ë”‡æ“– 148
 —¥ à«π¢Õß√à“ß°“¬∑’ºË¥‘ª°µ‘249 ·Õ𵇑®π 11, 59
 —≠≠“≥™’æ 12, 32, 200, 207 ·Õ≈øÉ“ 5
 —ß°– ’253 ·Õ≈øÉ“-∏“≈ —´’‡¡’¬ 1, 313
 “¬‚ª√µπ’ 1 Õ—µ√“°“√µ“¬ 280
 “√µ“â π·ø§‡µÕ√å 43 Õµ—√“°“√√Õ¥™’«‘µ 86, 137, 138, 140, 159, 235, 263
 ‡¡’¬√å‡≈◊Õ¥ 96, 97, 176, 306, 308, 312, 316 Õ—µ√“°“√‡°‘¥´È” 79
 “‡Àµÿ¢Õ߇≈Õ◊ ¥°”‡¥“‰À≈ 182 Õµ—√“°“√‡°‘¥‚√§ 280
 «à πª√–°Õ∫¢Õ߇≈Õ◊ ¥ 114, 153 Õ—≥±– 250
 ß‘Ë·ª≈°ª≈Õ¡„π®¡Ÿ° 183 Õ≈—µ√“´“«πå 126, 251
Õ¡‘¡‚Ÿπ‚°≈∫Ÿ≈π‘ 148, 151, 152, 153
À Õ“°“√§≈“â ¬‰¢âÀ«—¥ 63
Õ“°“√¢Õâ µ‘¥ 47
À≠ß‘∑Ë¡’¬’π’‚√§Œ’‚¡øï‡≈’¬·ΩßÕ¬“à ß·ππà Õπ 49 Õ“°“√™“ª≈“¬¡◊Õª≈“¬‡∑“â 174
À≠ß‘∑’ÕË“®¡’¬’π‚√§Œ‚’¡ø‡ï ≈¬’·Ωß 50 Õ“°“√∂“à ¬‡À≈« 138
Àπ“â µ“·∫∫∏“≈ —´‡’¡’¬ 5, 11 Õ“°“√∑πµÕà  ¿“æÕ“°“»À𓫉¡‰à ¥â 168
À¡Ÿà‡≈Õ◊ ¥ 11, 148, 235, 236 Õ“°“√∑“ß√–∫∫∑“߇¥π‘Õ“À“√ 80
À≈Õ¥≈¡À¥µ—« 81 Õ“°“√∑“ß√–∫∫ª√– “∑ 175
À≈Õ¥≈¡Õ—°‡ ∫ 153 Õ“°“√∑“ß‚≈À‘µ«‘∑¬“ 176
À≈Õ¥‡≈Õ◊ ¥ “¬ –¥◊Õ√° 259 Õ“°“√‡≈Õ◊ ¥ÕÕ°∑“ß™Õà ߧ≈Õ¥ 195
À≈Õ¥‡≈Õ◊ ¥¥” 63, 64 Õ“°“√‰¡æà ÷ߪ√– ß§å 14
À≈Õ¥‡≈Õ◊ ¥·¥ß‚ªÉßæÕß 212 Õ“°“√‰¢â 243
À≈Õ¥‡≈◊Õ¥·¥ß„π ¡ÕßÕ¥ÿµπ— 226 Õ“°“√ª«¥¢âÕ 13, 61
À≈Õ¥‡≈Õ◊ ¥∑¡Ë’“‡≈’Ȭ߂æ√ß®¡°Ÿ 180
À≈Õ¥‡≈◊Õ¥‚ªßÉ æÕß 183

330 ¥™— π’

Õ“°“√ª«¥ª√–®”‡¥◊Õπ 206 ŒÕ√‚å ¡π∑À’Ë≈ßË—®“°√ß—‰¢à 192
Õ≥™Ÿ’««‘∑¬“ 284 ŒÕ√å‚¡π‡Õ ‚µ√‡®π 192, 197, 205
Õ≥柗π∏ÿ»“ µ√å¢Õß‚√§·Õ≈øÉ“-∏“≈ —´’‡¡¬’ 23 ŒÕ√‚å ¡π‚ª√‡® ‡µÕ‚√π 192, 197, 198, 205
Õ≥Ÿæπ—∏ÿ»“ µ√¢å Õß‚√§‡∫µ“â -∏“≈ —´’‡¡¬’ 1 Œ’‚¡‚°≈∫‘π 1, 7, 10, 16, 25, 28, 29, 32, 64, 130, 137,
Õ≥Ÿæπ—∏ÿ»“ µ√¢å Õߌ‚’¡ø‡ï ≈¬’ 35
ÕÕ°´‡‘®π 32, 126, 183, 282, 306 165, 168, 242, 249, 261, 282, 288, 289
ÕÕ°´‘‡®πµ”Ë 283 Œ’‚¡‚°≈∫π‘∑’ˉ¡à‡ ∂’¬√ 27
Õ®ÿ®“√–¥” 170 Œ‚’¡øï‡≈’¬ 35, 40, 48, 110, 183, 266
Õ∫ÿµ—‘°“√≥å 35, 75, 226, 227, 243, 263, 291 Œ’‚¡ø‡ï ≈¬’ ´’111
Œ‚’¡ø‡ï ≈’¬ ∫’35, 266
Œ Œ’‚¡ø‡ï ≈’¬ ‡Õ 35, 41, 46, 111, 112, 240, 291
ŒÕ√å‚¡π 191 Œ‚’¡øï‡≈’¬ ‡Õ ™π¥‘√ÿπ·√ß 37, 43, 266, 292
ŒÕ√‚å ¡π∑’Ë √â“߇©æ“–∑’Ë193 Œ‚’¡øï‡≈’¬ ‡Õ ™π¥‘‰¡à√πÿ·√ß 38, 302, 303
ŒÕ√å‚¡π∑’ÀË≈Ëß—®“° ¡Õß 191 Œ’¡ 1
Œ¡’“‚µ§√‘µ 7, 29, 168
‰Œ‚ª∑“≈“¡—  191

Õ¿∏‘ “π»æ— ∑å(‰∑¬-Õß— °ƒ…)
Glossary (Thai-English)

§”»æ— ∑å §«“¡À¡“¬

°√¥Õ–¡‚‘π °
°√¥Õπ‘∑√¬’™å π¥‘ÕÕà π Amino acid
°√–¥°Ÿ§¥ Weak organic acid
°√–¥°Ÿº¥‘√ªŸ Scoliosis
°√–¥°ŸÕÕà π Bone deformity
°√–∫«π°“√·¢ßÁµ«—¢Õ߇≈Õ◊ ¥ Cartilage
°√–∫«π°“√ √“â ߇¡¥Á‡≈Õ◊ ¥ Coagulation pathway
°√–∫«π°“√ ß—‡§√“–À°å ≈µŸ“‰∏‚Õπ Hematopoiesis
°≈¡àÿ‰¡¡à Õ’“°“√· ¥ß∑“ߧ≈π‘°‘ Glutathione metabolism
°≈¡àÿ¬Õà ¬ IgG Asymptomatic
°≈¡ÿà Õ“°“√∏“≈ —´‡’¡¬’ IgG subclass
°Õâ π‡¥¬’Ë« Thalassemia syndromes
°Õâ π„µºâ «‘Àπß— Solitary
°Õâ π ”≈∑’„Ë’ ‡à ¢“â ‰ª„π™Õà ߧ≈Õ¥ Subcutaneous mass
°Õâ πÀ≈“¬µ”·Àπßà Tampon
°“√°¥À“â ¡‡≈Õ◊ ¥„π‚æ√ß®¡°Ÿ «à πÀπ“â Multifocal disease
°“√°√–µπÿâ °“√ √“â ß Hb F Anterior nasal packing
°“√°≈“¬æπ—∏„å π√–¥∫—¬π’ Induction of Hb F
°“√°≈“¬æπ—∏åÿ Gene mutation
°“√°≈“¬æπ—∏‡ÿå ©æ“–∑’Ë Mutation
°“√°≈“¬æπ—∏∑ÿå ‡Ë’°¥‘¢π÷È„π¿“¬À≈ß— Point mutation
°“√°≈“¬æπ—∏∑åÿ¡’Ë·’µ°à ”‡π¥‘ Acquired mutation
°“√‡°∫Á‡´≈≈µå πâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥®“°‰¢°√–¥°Ÿ Germline mutation
°“√‡°¥‘æß—º¥◊ „πªÕ¥ Bone marrow harvest
°“√‡°¥‘√∑Ÿ–≈¢ÿÕߺπß—°πÈ—™Õà ß®¡°Ÿ Pulmonary fibrosis
°“√¢¬“¬¢Õ߉¢°√–¥°Ÿ·≈–‚√§∑“ß°√–¥°Ÿ Septal perforation
°“√¢≈∫‘Àπß—À¡âÿª≈“¬Õ«¬—«–‡æ» Bone marrow expansion and bone disease
°“√¢“¥À“¬¢π“¥‡≈°Á Circumcision
°“√¢“¥À“¬¢π“¥„À≠à Small deletion
°“√¢“¥À“¬¢Õ߬π’ Large deletion
Gene deletion

Õ¿∏‘ “π»—æ∑å (‰∑¬-Õß— °ƒ…) Glossary (Thai-English) 355

°“√¢“¥À“¬∑ßÈ—À¡¥¢Õ߬π’ Complete gene deletion
°“√¢“¥À“¬·∫∫„À¡à Novel deletion
°“√¢“¥Õ¡‘¡‚Ÿπ‚°≈∫≈Ÿπ‘™π¥‘ IgA Selective IgA deficiency
°“√¢“¥·Õπµ∫‘Õ¥∑’®’Ë”‡æ“– Specific antibody deficiency
°“√®∫—°≈¡àÿ°π—¢Õ߇°≈¥Á‡≈Õ◊ ¥ Platelet aggregation
°“√®‚È’¥¬„™°â √–· ‰øø“Ñ Electrocauterization
°“√‡®√≠‘ ‡µ∫‘‚µ™“â Growth retardation
°“√‡®√∫‘‡µ∫‘‚µ∑ºË’¥‘ª°µ„‘π§√√¿å Prenatal growth retardation
°“√©¥’ “√Õ¥ÿÀ≈Õ¥‡≈Õ◊ ¥·¥ß Arterial embolization
°“√¥”‡ππ‘‚√§ Natural history
°“√¥¥Ÿ´¡÷∑∑Ë’“߇¥π‘Õ“À“√≈¥≈ß Malabsorption
°“√¥‡Ÿæ» Sex determination
°“√¥·Ÿ≈√°—…“∑∫Ë’“â π Home-Based care
°“√‰¥√â ∫—‡≈Õ◊ ¥„π√–À«“à ߵߗȧ√√¿å Intrauterine transfusion
°“√‰¥√â ∫—‡≈Õ◊ ¥‡ªπì ª√–®” Regular blood transfusion
°“√µ°‰¢à Ovulatory
°“√µ√«®°√Õß°“√°≈“¬æπ—∏ÿå Mutation screening
°“√µ√«®°“√µß—ȧ√√¿å Pregnancy test
°“√µ√«®§«“¡‡¢“â °π—‰¥â Compatibility testing
°“√µ√«®§¥—°√Õß‚√§„π°≈¡àÿª√–™“°√ Population screening
°“√µ√«®‚§√‚¡‚´¡«∏‘¡’“µ√∞“π Standard karyotyping
°“√µ√«®∑“ßÕ≥-Ÿ‡´≈≈æå π—∏»ÿ“ µ√å Molecular cytogenetic
°“√µ√«®∑“ßÕ≥æŸπ—∏»ÿ“ µ√å Molecular genetic testing
°“√µ√«®∑“ßÕÕâ ¡ Indirect method
°“√µ√«®«‡‘§√“–À™å π¥‘¢Õߌ‚’¡‚°≈∫π‘ Hemoglobin typing
°“√µ√«®«‡‘§√“–À≈å ”¥∫—𫑧≈‚’Õ‰∑¥å Direct DNA sequencing
°“√µ√«®«π‘®‘©¬—°Õà π¡°’“√Ωßí µ«—¢Õßµ«—ÕÕà π Preimplantation genetic diagnosis
°“√µ√«®À“°“√°≈“¬æπ—∏¢åÿÕ߬π’ Mutation analysis
°“√µ√«®À“°“√°≈“¬æπ—∏‚åÿ¥¬µ√ß Direct mutation analysis
°“√µÕà √Õß Bargaining
°“√µ¥—°√–‡æ“–Õ“À“√ Gastrectomy
°“√µ¥—¡“â ¡ Splenectomy
°“√µ¥‘‡™ÕÈ◊ ©«¬‚Õ°“  Opportunistic infection
°“√·µ°¢Õ߇¡¥Á‡≈Õ◊ ¥·¥ß Hemolysis

356 Õ¿∏‘ “π»æ— ∑å (‰∑¬-Õß— °ƒ…) Glossary (Thai-English)

°“√·µ°¢Õ߇¡¥Á‡≈Õ◊ ¥·¥ßπÕ°À≈Õ¥‡≈Õ◊ ¥ Extravascular hemolysis
°“√·µ°¢Õ߇¡¥Á‡≈Õ◊ ¥·¥ß„πÀ≈Õ¥‡≈Õ◊ ¥ Intravascular hemolysis
°“√∂¥∂Õ¬ Regression
°“√∂“à ¬∑Õ¥·∫∫¬π’¥Õâ ¬∫π‚§√‚¡‚´¡∏√√¡¥“ Autosomal recessive
°“√∂“à ¬∑Õ¥·∫∫¬π’¥Õâ ¬∫π‚§√‚¡‚´¡‡æ»À≠ß‘ X-linked recessive
°“√∂“à ¬¿“æ√ß— ∑’√«ßÕ° Chest X-ray
°“√∂“à ¬‡≈Õ◊ ¥ Exchange transfusion
°“√∑∫∑«π Rehearse
°“√∑”ß“π¢ÕßÀ«—„®ÀÕâ ß≈“à ß´“â ¬ Left ventricular ejection fraction
°“√∑”Õ≈—µ√“´“«¥∑å “ß™Õà ߧ≈Õ¥√«à ¡°∫—°“√©¥’π”È Saline infusion sonohysterography
‡°≈Õ◊ ‡¢“â ‰ª„π‚æ√ß¡¥≈°Ÿ
°“√·∑√°‡æ¡Ë‘¢Õ߬π’ Gene insertion
°“√∫π—∑°÷¢Õâ ¡≈Ÿ Agenda
°“√·∫ßà µ«— Proliferative
°“√ª≈°Ÿ∂“à ¬‡´≈≈µå πâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥∑‡Ë’¢“â °π— Matched-related donor
°“√ª≈°Ÿ∂“à ¬‡´≈≈µå πâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥‚¥¬„™‡â ´≈≈å Allogeneic hematopoietic stem cell
µπâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥¢ÕߺÕâŸπ◊Ë transplantation
°“√ª≈°Ÿ∂“à ¬‡´≈≈µå πâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥‚¥¬„™‡â ´≈≈µå πâ °”‡π¥‘ Autologous hematopoietic stem cell
‡¡¥Á‡≈Õ◊ ¥¢Õßµ«—‡Õß transplantation
°“√ª≈°Ÿ∂“à ¬‰∑¡ — Thymus transplantation
°“√·ºµà «—ÕÕ° Spreading
°“√æπà ®¡°Ÿ Intranasal spray
°“√欓°√≥‚å √§ Prognosis
°“√‡æ¡‘Ë®”π«π¢Õ߇¡¥Á‡≈Õ◊ ¥¢“«™π¥‘Lymphocyte Lymphocyte proliferation
°“√¡‡’≈Õ◊ ¥ÕÕ°®“°·º≈µ¥— “¬ –¥Õ◊ Umbilical stump bleeding
°“√¬π◊ ¬π—°“√«π‘®‘©¬—‚√§ Diagnostic confirmation
°“√√°—…“ Treatment
°“√√°—…“¥«â ¬¬π’∫”∫¥— Gene therapy
°“√≈“â ߉µ Dialysis
°“√«π‘®‘©¬—‚√§°Õà π§≈Õ¥ Prenatal diagnosis
°“√ √“â ߇¡¥Á‡≈Õ◊ ¥·¥ß¢Õ߉¢°√–¥°Ÿ Erythropoiesis
°“√ √“â ߇¡¥Á‡≈Õ◊ ¥·¥ß·≈–æ≤—π“‡¡¥Á‡≈Õ◊ ¥·¥ß Erythroid maturation
°“√ ≈∫—¥“â π¢Õ߬π’ Gene inversion
°“√ Õà ß°≈Õâ ß Endoscope

Õ¿∏‘ “π»æ— ∑å (‰∑¬-Õß— °ƒ…) Glossary (Thai-English) 357

°“√ Õà ß°≈Õâ ßµ√«®¿“¬„π‚æ√ß¡¥≈°Ÿ Hysteroscopy
°“√À¥µ«—¢Õß≈¡‘ˇ≈Õ◊ ¥ Clot retraction
°“√À≈ß≈¡◊ Dementia
°“√À“¬¢Õß·º≈®–™“â °«“à ª°µ‘ Poor wound healing
°“√„À‡â ≈Õ◊ ¥ Blood transfusion
°“√„À‡â ≈Õ◊ ¥ª√¡‘“≥¡“° Massive transfusion
°“√‰À≈‡«¬’π¢Õ߇≈Õ◊ ¥‡√«Á High flow
°“√‰À≈‡«¬’π‡≈Õ◊ ¥™“â Low flow
°“√Õ∏∫‘“¬ Explain
°“√Õ°—‡ ∫¢Õ߉µ Nephritis
°“√Õ¥ÿµπ—√®Ÿ¡°Ÿ¢“â ߇¥¬’« Unilateral nasal obstruction
‡°≈¥Á‡≈Õ◊ ¥¢π“¥‡≈°Á Small platelet
‡°≈¥Á‡≈Õ◊ ¥¢π“¥„À≠à Giant platelet
‡°≈¥Á‡≈Õ◊ ¥‡¢¡â ¢πâ Platelet concentrate
‡°≈¥Á‡≈Õ◊ ¥µË” Thrombocytopenia
‡°≈¥Á‡≈Õ◊ ¥∑”Àπ“â ∑ºË’¥‘ª°µ‘ Platelet dysfunction
‡°≈¥Á‡≈Õ◊ ¥¡®’”π«π≈¥≈ß·µ‡à 欒ßÕ¬“à ߇¥¬’« Isolated thrombocytopenia
‚°√∏ Anger

¢

¢∫«π°“√µ“â π°“√·¢ßÁµ«—¢Õ߇≈Õ◊ ¥ Anticoagulant pathway
¢∫«π°“√ √“â ߇¡¥Á‡≈Õ◊ ¥·¥ß„π‰¢°√–¥°Ÿ‰¡¡à ª’√– ∑‘∏¿‘“æ Ineffective erythropoiesis
¢Õâ º¥‘√ªŸ·≈–¢Õâ æ°‘“√ Joint deformation
‰¢°√–¥°Ÿ Bone marrow

§≈πË◊ ‡ ¬’ߧ«“¡∂ Ë’ߟ™π¥‘ doppler §
§«“¡°√–®“à ߢÕߢÕâ ¡≈Ÿ Doppler ultrasound
§«“¡§ß ¿“æ Elicit
§«“¡§¥‘√‡‘√¡‘Ë≈Õß∑” ß‘˵“à ßÊ Stability
§«“¡®”‡æ“– Initiativity
§«“¡‡ªπì µ«—¢Õßµ«—‡Õß Specificity
§«“¡º¥‘ª°µ¢‘Õߺπß—‡¡¥Á‡≈Õ◊ ¥·¥ß Autonomy
§«“¡º¥‘ª°µ¢‘Õ߬π’‡æ¬’ß¬π’‡¥¬’« RBC membranopathy
Single gene disorder

358 Õ¿∏‘ “π»æ— ∑å (‰∑¬-Õ—ß°ƒ…) Glossary (Thai-English)

§«“¡º¥‘ª°µ¢‘Õ߇Õπ‰´¡¢å Õ߇¡¥Á‡≈Õ◊ ¥·¥ß RBC enzymopathy
§«“¡º¥‘ª°µ¢‘Õߌ‚’¡‚°≈∫π‘ Hemoglobinopathy
§«“¡º¥‘ª°µ∑‘“ß√ªŸ√“à ߢÕßÀ≈Õ¥‡≈Õ◊ ¥ Vascular malformation
§«“¡º¥‘ª°µ√‘«à ¡°π—¢ÕßÀ≈Õ¥‡≈Õ◊ ¥·¥ß·≈–À≈Õ¥‡≈Õ◊ ¥¥” Arteriovenous malformation
§«“¡√ Ÿâ °÷‰««â “ß„® Trust
§«“¡‰« Sensitivity
§«“¡ ¡—æπ—∏¢å Õß≈°—…≥–∑“ßæπ—∏°ÿ√√¡·≈– Genotype-phenotype correlation
≈°—…≥–∑“ߧ≈π‘°‘
§«“¡Àπ“·ππà ¢Õß°√–¥°ŸπÕâ ¬°«“à ª°µ‘ Low bone density for chronological age
§Õ≈≈“‡®π Collagen
§“à §«“¡‡¢¡â ¢πâ ¢Õ߇≈Õ◊ ¥ Hematocrit
§≥ÿ ¿“æ‰ø∫√‚‘π‡®πº¥‘ª°µ‘ Dysfibrinogenemia
‡§√Õ◊Ëß™«à ¬©¥’¬“ Infusion pump
‚§√ß √“â ß„π·π«µß—È Vertical structure
‚§√ß √“â ß„π·π«πÕπ Horizontal structure

®È”‡≈Õ◊ ¥ ®
®¥ÿ‡≈Õ◊ ¥ÕÕ° Purpura
Petechiae

‡©¬’∫æ≈π— ©
Acute

‡´≈≈‰å ¢¡π— ´
‡´≈≈µå πâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥ Adipocyte
‡´≈≈µå πâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥®“° “¬ –¥Õ◊ √° Hematopoietic stem cell
‡´≈≈µå πâ °”‡π¥‘‡¡¥Á‡≈Õ◊ ¥∑„Ë’Àºâ ªâŸ«É ¬‰¡µà ¥‘ Cord blood stem cell
‡´≈≈æå ‡’Ë≈¬È’ß Graft rejection
‡´≈≈‡å ¡¥Á‡≈Õ◊ ¥·¥ßµ«—ÕÕà π Stromal cell
‡´≈≈‡å ¬Õ◊Ë∫≈ÿ”‰ â Erythroid progenitor cell
‡´≈≈‡å ¬Õ◊Ë∫Àÿ≈Õ¥‡≈Õ◊ ¥ Enterocyte
Endothelial cell

Õ¿‘∏“π»æ— ∑å (‰∑¬-Õ—ß°ƒ…) Glossary (Thai-English) 359

¥™—π‡’¡¥Á‡≈Õ◊ ¥·¥ß ¥
¥“à ߢ“« Red cell indices
‡¥°Á°≈¡àÿ∑µË’Õâ ß°“√‡«≈“„π°“√ª√∫—µ«— Vitiligo
‡¥°Á°≈¡àÿ‡≈¬’Èßß“à ¬ Slow to warm up child
‡¥°Á°≈¡ÿà ‡≈¬È’߬“° Easy child
µÕâ °√–®° Difficult child
µÕ∫ πÕß
µÕà ¡„µ â ¡Õß µ
µÕà ¡„µ â ¡Õß «à πÀπ“â Cataract
µ∫—‚µ Responder
µ«—ÕÕà π¡π…ÿ¬„å π§√√¿å Pituitary gland
µ“¢‡’È°¬’® Anterior pituitary gland
µ“‡¢ Hepatomegaly
µßË‘‡πÕÈ◊ ‡¬ÕË◊ ∫‚ÿæ√ß¡¥≈°Ÿ Embryonic
∂«Ë—ª“°Õ“â Amblyopia
∂ßÿ‰¢·à ¥ß Strabismus
∑Õà π”ȵ“Õ¥ÿµπ— Endometrial polyp
∑Õà πÈ”‡À≈Õ◊ ß
∑“ß™π—È„µºâ «‘Àπß— ∂
∑“ßÀ≈Õ¥‡≈Õ◊ ¥¥” Fava beans
∏“µ ÿß—°– ’ Yolk sac
∏“µ‡ÿÀ≈°Á‡ √¡‘∑¥·∑π
∑
Nasolacrimal duct obstruction
Lymphatic vessel
Subcutaneous route
Intravenous route

∏
Zinc
Iron supplement

360 Õ¿‘∏“π»æ— ∑å (‰∑¬-Õ—ß°ƒ…) Glossary (Thai-English)

πÈ”∑«à ¡ªÕ¥ π
πÈ”∑‡Ë’°π‘ Pulmonary edema
π«Ë‘„π∂ßÿπÈ”¥’ Volume overload
π«‘ÈÀ«—·¡¡à Õ◊ º¥‘√ªŸ Gall stone
‡πÕÈ◊ ßÕ°¢ÕßÀ≈Õ¥‡≈Õ◊ ¥ Triphalangeal thumb
‡πÕ◊ÈßÕ°„π®¡°Ÿ™π¥‘·æ∫æ≈‘‚≈¡“ Vascular tumor
‡πÕÈ◊ ßÕ°∑“߇¥π‘πÈ”‡À≈Õ◊ ß Nasal papilloma
‡πÕÈ◊ ßÕ°¡¥≈°Ÿ Lymphatic tumor
Myoma uteri

‡∫µ“â ∫
‡∫µ“â -∏“≈ —´‡’¡¬’ Beta
β-thalassemia

ª

ªØ°‘√‘¬‘“¿¡Ÿ·‘æ‡â ©¬’∫æ≈π—√πÿ·√ß Anaphylactic reaction
ªØ‡‘ ∏ Denial
ª√–®”‡¥Õ◊ π Menses
ª√–®”‡¥Õ◊ π¢“¥À“¬‰ªÀ≈ß—®“°∑‡Ë’§¬¡ª’√–®”‡¥Õ◊ π·≈«â Secondary amenorrhea
ªπóô  ·’¥ß Erythematous patch
·ªßÑ  “≈’ Starch
‚ª√‡® µπ‘ Progestin
‚ª√µπ’µ“â π°“√·¢ßÁµ«—¢Õ߇≈Õ◊ ¥ Anticoagulation protein
‚ª√µπ’∑™’Ë«à ¬„π°“√·¢ßÁµ«—¢Õ߇≈Õ◊ ¥ Coagulation factor

ºπß—°π—È™Õà ß®¡°Ÿ º
ºπß—°π—È‚æ√ß®¡°Ÿº¥‘√ªŸ Nasal septum
ºπß—¢“â ß®¡°Ÿ Septal deviation
º“â °Õ´™∫ÿ«“ ≈π‘¡«â π Lateral nasal wall
Vaseline gauze

Õ¿∏‘ “π»—æ∑å (‰∑¬-Õß— °ƒ…) Glossary (Thai-English) 361

æ≈ß—·≈–§«“¡‡¢¡â ·¢ßÁ æ
æ≤— π“°“√™“â Empowerment
æ“À–¢Õß∏“≈ —´‡’¡¬’ Global developmental delay
æπ◊ÈÕ“√¡≥å Thalassemia trait
‚æ√ßÀ≈Õ¥‡≈Õ◊ ¥¥”„π ¡ÕßÕ¥ÿµπ— Temperament
Cerebral sinovenous thrombosis

øÕ ‚ø≈ª‘¥î ø
·ø§‡µÕ√å Phospholipid
·ø§‡µÕ√å VIII ‡¢¡â ¢πâ Factor
·ø§‡µÕ√‡å ¢¡â ¢πâ FVIII concentrate
‰ø∫√‚‘π‡®π Factor concentrate
Fibrinogen

¿“«–°√–¥°Ÿ∫“ß ¿
¿“«–°√–¥°Ÿæ√πÿ Osteopenia
¿“«–°“√‡°¥‘ “√µ“â π·ø§‡µÕ√å Osteoporosis
¿“«–‡°≈¥Á‡≈Õ◊ ¥µË”·≈–‡°≈¥Á‡≈Õ◊ ¥¢π“¥„À≠à Factor inhibitor
¿“«–‰´π —Õ°—‡ ∫ Macrothrombocytopenia
¿“«–µÕà ¡À¡«°‰µ∑”ß“π∫°æ√Õà ß Sinusitis
¿“«–µ«—‡µ¬È’ Adrenal insufficiency
¿“«–∑¡Ë’°’“√°”®¥—À√Õ◊ ∑”≈“¬‡¡¥Á‡≈Õ◊ ¥‚¥¬¡“â ¡ Short stature
¿“«–∑¡Ë’°’“√·¢ßÁµ«—¢Õ߇≈Õ◊ ¥º¥‘ª°µ‘ Hypersplenism
¿“«–∑¡Ë’‡’¡¥Á‡≈Õ◊ ¥¢“« lymphocyte µ”Ë Prothrombotic disorder
¿“«–ª√–®”‡¥Õ◊ πÕÕ°¡“° Lymphopenia
¿“«–‡ªπì Àπ¡àÿ “«™“â Hypermenorrhea
¿“«–æ√Õà ߉∑√Õ¬¥Œå Õ√‚å ¡π Hypogonadism
¿“«–æ√Õà ßæ“√“‰∑√Õ¬¥Œå Õ√‚å ¡π Primary hypothyroidism
¿“«–‰ø∫√‚‘π‡®πµ”Ë Hypoparathyroidism
¿“«–‡¡¥Á‡≈Õ◊ ¥¢“«µ”ËÕ¬“à ß√πÿ·√ß Hypofibrinogenemia
¿“«–‰¡¡à ‰’ø∫√‚‘π‡®π Agranulocytosis
¿“«–‡¬Õ◊Ë∫‚ÿæ√ß¡¥≈°ŸÀ𓵫— Afibrinogenemia
¿“«–√πÿ·√ß∂ß÷™«’µ‘ Endometrial hyperplasia
Life threatening

362 Õ¿∏‘ “π»æ— ∑å (‰∑¬-Õß— °ƒ…) Glossary (Thai-English)

¿“«–≈¡‘ˇ≈Õ◊ ¥Õ¥ÿµπ— Thromboembolism
¿“«–‡≈Õ◊ ¥ÕÕ°ß“à ¬®“°°“√·¢ßÁµ«—¢Õ߇≈Õ◊ ¥·µ°à ”‡π¥‘ Rare inherited coagulation disorder
Dysfunctional uterine bleeding
™π¥‘∑æË’∫‰¡∫à Õà ¬ Bleeding disorder
¿“«–‡≈Õ◊ ¥ÕÕ°®“°‚æ√ß¡¥≈°Ÿ‚¥¬‰¡æà ∫ “‡Àµ∑ÿ“ß Iron deficiency anemia
Megaloblastic anemia
欓∏«‘∑‘¬“ Pancytopenia
¿“«–‡≈Õ◊ ¥ÕÕ°º¥‘ª°µ‘ Post-traumatic stress disorder
¿“«–‚≈Àµ‘®“ß®“°°“√¢“¥∏“µ‡ÿÀ≈°Á Body disproportion
¿“«–‚≈Àµ‘®“ß®“°°“√¢“¥‚ø‡≈µ «µ‘“¡π‘∫’12 Dehydration
¿“«–‚≈Àµ‘®“ß√«à ¡°∫—‡¡¥Á‡≈Õ◊ ¥¢“«·≈–‡°≈¥Á‡≈Õ◊ ¥µË” Atherosclerosis
¿“«– –‡∑Õ◊ π¢«≠—À≈ß—‡Àµ°ÿ“√≥√å πÿ·√ß Iron overload
¿“«– ¥— «à π√“à ß°“¬º¥‘ª°µ‘ Antiphospholipid antibody
¿“«– ≠Ÿ ‡ ¬’πÈ” Immune deficiency
¿“«–À≈Õ¥‡≈Õ◊ ¥·¥ß·¢ßÁµ«—
¿“«–‡À≈°Á‡°π‘
¿¡Ÿ§‘¡ÿâ °π—µÕà øÕ ‚ø≈ª‘¥î
¿¡Ÿ§‘¡ÿâ °π—∫°æ√Õà ß

¡

¡–‡√ßÁ°≈“â ¡‡πÕ◊È≈“¬ Rhabdomyosarcoma
¡–‡√ßÁµÕà ¡π”ȇÀ≈Õ◊ ß Malignant lymphoma
¡–‡√ßÁµÕà ¡À¡«°‰µ™π¥‘∑¡’˵’πâ °”‡π¥‘„π‚æ√ß®¡°Ÿ Esthesioneuroblastoma
¡“â ¡‚µ Splenomegaly
‡¡¥Á‡≈Õ◊ ¥·¥ßµ¥‘ ®’“ß Hypochromia
‡¡¥Á‡≈Õ◊ ¥·¥ß¡¢’π“¥·µ°µ“à ß°π— Anisocytosis
‡¡¥Á‡≈Õ◊ ¥·¥ß¡¢’𓥇≈°Á Microcytosis
‰¡‰à ¥‡â §≈Õ◊Ëπ‰À« Immobilization
‰¡µà Õ∫ πÕß Non-responder
‰¡¡à °’“√µ°‰¢à Anovulatory
‰¡¡à ª’√–®”‡¥Õ◊ π Primary amenorrhea

Õ¿∏‘ “π»—æ∑å (‰∑¬-Õ—ß°ƒ…) Glossary (Thai-English) 363

¬Õ¡√∫— ¬
¬“°¥¿¡Ÿ§‘¡âÿ°π— Acceptance
¬“¢∫—‡À≈°Á Immunosuppressive drug
¬“µ“â π°“√Õ°—‡ ∫∑‰’Ë¡„à ™ à ‡µ¬’√Õ¬¥å Iron chelation
¬“π”È Nonsteroidal anti-inflammatory drugs
¬“‡¡¥Á Syrup
¬“≈–≈“¬≈¡‘ˇ≈Õ◊ ¥ Tablet
¬“ ‡µ¬’√Õ¬¥æå πà ®¡°Ÿ Thrombolytic agent
¬“À¥À≈Õ¥‡≈Õ◊ ¥™π¥‘æπà ®¡°Ÿ Topical nasal steroid
‡¬Õ◊Ë∫∑ÿ“߇¥π‘À“¬„® Topical decongestant
‡¬ÕË◊ ∫‚ÿæ√ß¡¥≈°Ÿ Respiratory mucosa
‡¬ÕË◊ ∫‚ÿæ√ß¡¥≈°Ÿ‡®√≠‘º¥‘∑’Ë Endometrium
Adenomyosis

√ Hyperpigmentation
√Õ¬¥” Conception
√–¬–ªØ ‘π∏‘ Nasolacrimal duct
√‡Ÿª¥î ¢Õß∑Õà πÈ”µ“ Control
√ âŸ°÷§«∫§¡ÿ ∂“π°“√≥‰å ¥â Chronic
‡√ÕÈ◊ √ß— Gravity
·√ß‚π¡â ∂«à ß Postmenopausal osteoporosis
‚√§°√–¥°Ÿæ√πÿ„πºÀŸâ ≠ß‘∑«’ˬ—À¡¥ª√–®”‡¥Õ◊ π Aplastic anemia
‚√§‰¢°√–¥°ŸΩÕÉ Combined B- and T- cell immunodeficiency
‚√§∑¡’˧’«“¡º¥‘ª°µ¢‘Õ߇¡¥Á‡≈Õ◊ ¥¢“« B ·≈– T cell Complement deficiency
‚√§∑¡Ë’§’«“¡ ¡—æπ—∏°å ∫—°“√¢“¥ complement Diabetes mellitus
‚√§‡∫“À«“π Autoimmune disorder
‚√§¿¡Ÿ§‘¡âÿ°π—µ“â πµπ‡Õß Primary immunodeficiency disease
‚√§¿¡Ÿ§‘¡ÿâ °π—∫°æ√Õà ߪ∞¡¿¡Ÿ‘ Osteosarcoma
‚√§¡–‡√ßÁ°√–¥°Ÿ Solid tumor
‚√§¡–‡√ßÁ¢ÕßÕ«¬—«–·∫∫∑‡Ë’ªπì °Õâ π Epilepsy
‚√§≈¡™°— Cerebrovascular disease
‚√§À≈Õ¥‡≈Õ◊ ¥ ¡Õß

364 Õ¿‘∏“π»æ— ∑å (‰∑¬-Õß— °ƒ…) Glossary (Thai-English)

≈°—…≥–∑“߇æ»∑µÿ¬‘¿¡Ÿ‘ ≈
≈πÈ‘‡≈¬’Ëπ·¥ß Secondary sex characteristics
≈¡Ë‘‡≈Õ◊ ¥„πÀÕâ ßÀ«—„® Smooth and beefy tongue
≈¡‘ˇ≈Õ◊ ¥Õ¥ÿµπ—∑ÀË’≈Õ¥‡≈Õ◊ ¥·¥ß„πªÕ¥ Intracardiac thrombus
≈¡Ë‘‡≈Õ◊ ¥Õ¥ÿµπ—„πÀ≈Õ¥‡≈Õ◊ ¥¥”∑‰’˵ Pulmonary embolism
≈¡‘ˇ≈Õ◊ ¥Õ¥ÿµπ—„πÀ≈Õ¥‡≈Õ◊ ¥¥”∑ÕË’¬™àŸπÈ—≈°÷ Renal vein thrombosis
‡≈Õ◊ ¥°”‡¥“ÕÕ°®“°¥“â πÀπ“â ¢Õß‚æ√ß®¡°Ÿ Deep vein thrombosis
‡≈Õ◊ ¥°”‡¥“ÕÕ°®“°¥“â πÀ≈ß—¢Õß‚æ√ß®¡°Ÿ Anterior epistaxis
‡≈Õ◊ ¥®“° “¬ –¥Õ◊ √° Posterior epistaxis
‡≈Õ◊ ¥ÕÕ°„µÀâ πß—»√’…– Umbilical cord blood
‡≈Õ◊ ¥ÕÕ°„π√–∫∫∑“߇¥π‘Õ“À“√ Subgaleal hemorrhage
‡≈Õ◊ ¥ÕÕ°„π ¡Õß Gastrointestinal bleeding
‚≈Àµ‘®“ß ´¥’ À√Õ◊ ‡≈Õ◊ ¥®“ß Intracranial hemorrhage
«“ß·ºπ°“√√°—…“¥·Ÿ≈ Anemia
«µ‘“¡π‘∫’12
»√’…–‡≈°Á «
‡»√“â Health plan
 “¬ «πª í  “«– Cobalamin
 “√µ“â π
 “√µ“â π™«—Ë§√“« »
 “√≈–≈“¬§«“¡‡¢¡â ¢πâ µ”Ë Microcephaly
Àπ“â µ“·∫∫∏“≈ —´‡’¡¬’ Depression
Àπ“â ∑¢’ËÕß‚ª√µπ’
À¡‡Ÿà ≈Õ◊ ¥ Rh  
À¡‡Ÿà ≈Õ◊ ¥ ABO Foley catheter
Inhibitor
Transient inhibitor
Hypotonic solution

À
Thalassemia facies
Protein function
Rh D typing
ABO grouping

Õ¿‘∏“π»—æ∑å (‰∑¬-Õ—ß°ƒ…) Glossary (Thai-English) 365

À≈Õ¥‡≈Õ◊ ¥¥” Vein
À≈Õ¥‡≈Õ◊ ¥·¥ß Artery
À≈Õ¥‡≈Õ◊ ¥·¥ß„π ¡ÕßÕ¥ÿµπ— Arterial ischemic stroke
À≈Õ¥‡≈Õ◊ ¥„π ¡Õß·µ° Hemorrhagic stroke
À≈Õ¥‡≈Õ◊ ¥„π ¡ÕßÕ¥ÿµπ— Ischemic stroke
À≈Õ¥‡≈Õ◊ ¥ΩÕ¬ Capillary
À≈Õ¥Õ“À“√µ∫’ Esophageal stricture

Õµ—√“°“√‡°¥‘‚√§ Õ
Õµ—√“°“√µ“¬ Morbidity
Õ“°“√¢Õâ µ¥‘ Mortality
Õ“°“√§≈“â ¬‰¢Àâ «¥— Contracture
Õ“°“√™“ª≈“¬¡Õ◊ ª≈“¬‡∑“â Flu-like
Õ“°“√∂“à ¬‡À≈«¡‰’¢¡π—ªπ Peripheral neuropathy
Õ“¬°ÿ√–¥°Ÿ Steatorrhea
Õ“À“√‡ √¡‘∑¡’Ë∏’“µ‡ÿÀ≈°Á ßŸ Bone age
Õ¡‘¡‚Ÿπ‚°≈∫≈Ÿπ‘ Iron enriched food
‡Õ°´‡√¬°å √–¥°Ÿ π—À≈ß— Immunoglobulin
‡Õ°´‡√¬§å Õ¡æ«‘‡µÕ√Àå ≈Õ¥‡≈Õ◊ ¥¥”/·¥ß Lateral spine radiography
‡Õ¡ÁÕ“√‰å ÕÀ≈Õ¥‡≈Õ◊ ¥¥”/·¥ß Computed tomography venography/arterio-
·Õ𵇑®π graphy
·Õπµ∫‘Õ¥’ Magnetic resonance venography/arteriography
·Õπµ∫‘Õ¥µ’Õà ‡°≈¥Á‡≈Õ◊ ¥ Antigen
·Õπµ∫‘Õ¥∑’®’Ë”‡æ“– Antibody
·Õ≈ø“É Platelet antibody
·Õ≈ø“É -∏“≈ —´‡’¡¬’ Specific antibody
·Õ ‰æ√π‘ Alpha
α-thalassemia
Aspirin